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ABSTRACT 
 
Recent studies have demonstrated a turnover of cardiomyocytes throughout the 
adult life. Whether this regenerative potential is due to proliferation and 
differentiation of resident stem cells or to the dedifferentiation of adult 
cardiomyocytes remains unclear. Generation of new cardiomyocytes is critical 
for cardiac repair following myocardial injury; however the mechanisms by 
which injury responses modulate differentiation and proliferation of 
cardiomyocyte progenitors is not clear.  
In Study I, we show that sublethal apoptotic stimuli modulate the differentiation 
of mouse embryonic stem cells (ESC) into cardiomyocytes through a caspase-
dependent mechanism. This indicates a direct link between caspase activation 
and initiation of the cardiogenic programs. Further unfolding of these 
mechanisms may have significant implications for the understanding of the 
dynamics of cardiac regeneration after myocardial injury involving both 
exogenous and endogenous cell sources.  
The intrinsic regenerative capacity of human fetal cardiac mesenchymal stromal 
cells (MSCs) has not been fully characterized. In Study II our aim was to 
establish a culture protocol for large-scale expansion of human fetal cardiac 
MSCs with characteristics of cardiovascular progenitor cells. By culturing the 
cardiac MSCs on defined laminin (LN)-based substrata in combination with 
stimulation of the canonical Wnt/β-catenin pathway we could generate multi-
potent cells which could differentiate into endothelial, smooth muscle cells, and 
spontaneously beating cardiomyocytes. The expanded cardiac MSCs stained 
positive for the progenitor markers: Pdgfr-α, Isl1, and Nkx2.5, and 
subpopulations also expressed: Tbx18, Kdr, c-Kit, and Ssea-1. Our protocol for 
large-scale culture of human fetal cardiac MSCs enables future exploration of 
the regenerative functions of these cells in the context of myocardial injury in 
vitro and in vivo. 
Subsequently, in Study III we performed bioenergetic and metabolic profiling of 
human fetal cardiac MSCs as a tool for investigating metabolic changes in 
embryonic hearts during development. The critical role of metabolism in the 
active control of cell renewal and lineage specification has recently come into 
focus, and Wnt has been proposed as one of the signaling pathways which links 
energy metabolism to cell fate decision. In the MSCs derived from hearts of 
different gestational age, we observed an increase in oxidative metabolism 
during first trimester of development. Finally, stimulation of the canonical 
Wnt/β-catenin signaling pathway in hypoxia appeared to enhance long-term 
MSC expansion, and resulted in a cell population with higher cardiogenic 
differentiation potential. Our findings suggest that manipulation of metabolic 
signals may facilitate endogenous stem cell activation, tissue renewal and 
induction of cytoprotective properties. 
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1 INTRODUCTION 
 
1.1  HEART DEVELOPMENT 
 
The heart is one of the first organs that develop during embryogenesis and the first 
organ that displays function. During gastrulation, the process in which the three germ 
layers of an embryo are formed, a subset of epiblast cells moves as a sheet to the 
primitive streak and undergoes an epithelial-to-mesenchymal transition (EMT) (Gould 
et al. 2013).  The heart is derived from the mesodermal germ layer, which is specified 
into the cardiac mesoderm through the interaction of inductive and inhibitory signals 
from the adjacent endoderm and ectoderm (Figure 1)(Srivastava 2006). These signals 
include Wingless-related integration site (Wnt), fibroblast growth factor (Fgf), and 
transforming growth factor-β (Tgf-β) pathways leading to the activation of early 
cardiomyocyte transcriptional programs (Marvin et al. 2001, Harvey 2002, 
Buckingham et al. 2005, Lopez-Sanchez and Garcia-Martinez 2011, Brade et al. 2013, 
Spater et al. 2014). The next step in cardiogenesis is the specification and 
differentiation of progenitor cells through the development of specific heart fields 
(Buckingham et al. 2005, Kelly et al. 2014). The first heart field (FHF) forms the 
cardiac crescent in the anterior splanchnic mesoderm at approximately week 2 of 
human gestation (Brade et al. 2013, Kelly et al. 2014). In the third week of human 
gestation, the cardiac crescent fuses at the midline, and it forms the linear heart tube, 
which starts to beat around embryonic day 22 (Brade et al. 2013, Kelly et al. 2014). 
Subsequently, during week 4, the linear heart tube undergoes rightward 
looping (Zaffran et al. 2004), and it grows rapidly through cell proliferation and 
recruitment of subpharyngeal cells to the arterial and venous poles (Tirosh-Finkel et al. 
2006, van den Berg et al. 2009). The cells originating from the pharyngeal mesoderm 
migrate and enter the FHF-derived heart tube, differentiating into progenitors of the 
second heart field (SHF) (Figure 1) (Mjaatvedt et al. 2001, Waldo et al. 2001, Cai et al. 
2003, Kelly et al. 2014). SHF progenitors are defined by their expression of the LIM-
homeodomain transcription factor Islet-1 (Isl1), and they contribute to the atria, outflow 
tract (OFT), and the right ventricle, whereas the left ventricle mainly seems to be 
derived from the FHF cells, which are marked by their expression of T-box 
transcription factor 5 (Tbx5), NK2 homeobox 5 (Nkx2.5), and the ion channel 
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hyperpolarization-activated cyclic nucleotide-gated channel 4 (Hcn4) (Cai et al. 2003, 
Chien et al. 2008, Genead et al. 2010, Spater et al. 2013, Zhuang et al. 2013).  A recent 
study explored how different levels of Tbx5a and pituitary homeobox 2 (Pitx2) 
contribute to the development of the FHF and the SHF of a Zebrafish, where blocking 
of their respective actions led to heart dysfunction (Mosimann et al. 2015). These 
findings suggest that FHF and SHF progenitors may give rise to cardiomyocytes with 
distinctive physiological properties (Mosimann et al. 2015). 
The early embryonic heart tube consists of two cell layers, the endocardium and the 
myocardium. The third layer, the epicardium, is derived from the proepicardium, 
which in turn arises from the coelomic mesenchyme of the septum transversum 
roughly at embryonic day 21 (Manner et al. 2001). The embryonic proepicardial 
progenitor cells differentiate into cardiac fibroblasts, coronary vasculature, and to 
some extent into cardiomyocytes (Cai et al. 2008, Zhou et al. 2008). 
The fourth progenitor population involved in cardiogenesis consists of the cranial 
neural crest cells, and it arises from the dorsal neural tube (Keyte and Hutson 2012, 
Brade et al. 2013, Kelly et al. 2014). The neural crest cells are crucial for the 
septation of the OFT, the formation of heart valves, and the full parasympathetic 
innervation of the heart (Keyte and Hutson 2012, Brade et al. 2013, Kelly et al. 
2014). 
Through complex interactions of FHF and SHF progenitors with proepicardial and 
cranial neural crest cells, the fetal heart is septated into four defined chambers, and it 
connects to the aorta and the pulmonary trunk approximately during gestational week 
7 (Yi et al. 2010, Brade et al. 2013, Kelly et al. 2014). 
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1.2 CARDIOVASCULAR PROGENITORS 
 
In order to define cardiovascular progenitors, it is necessary to identify their origin in 
the embryonic heart and to organize them within the hierarchy of cardiogenesis. Only 
when we have a reliable map of fetal cardiovascular cell lineages can we look for the 
presence of endogenous stem cells and progenitors in the adult heart. 
A common primordial cardiovascular progenitor that gives rise to progenitors of both 
the FHF and SHF has been characterized by the expression of transcription factor 
brachyury (Bry), a member of the T-box family of genes, shown to be critical for 
mesoderm formation (Showell et al. 2004, Kattman et al. 2006, Yi et al. 2010). 
 
Figure 1. Mammalian Heart Development 
 
FHF cells form a crescent shape in the anterior embryo with SHF cells medial and anterior to 
the FHF (Second panel). SHF cells lie dorsal to the straight heart tube and begin to migrate 
(arrows) into the anterior and posterior ends of the tube to form the right ventricle (RV), 
conotruncus (CT), and part of the atria (A) (Third panel). Cardiac neural crest (CNC) cells 
also migrate (arrow) into the outflow tract from the neural folds to septate the outflow tract 
and pattern the aortic arch arteries (III, IV, and VI) (Fourth panel). The next step is septation 
of the ventricles, atria, and valves (AVV). V, ventricle; LV, left ventricle; LA, left atrium; 
RA, right atrium; AS, aortic sac; Ao, aorta; PA, pulmonary artery; RSCA, right subclavian 
artery; LSCA, left subclavian artery; RCA, right carotid artery; LCA, left carotid artery; DA, 
ductus arteriosus. Reprinted with the permission from the publisher of (Srivastava 2006) 
http://dx.doi.org/10.1016/j.cell.2006.09.003 
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Kattman and colleagues used Bry and kinase insert domain receptor (Kdr), also 
known as fetal liver kinase 1 (Flk-1), which encodes vascular endothelial growth 
factor receptor 2, to identify a population of cells with cardiovascular potential 
(Figure 2) (Kattman et al. 2006, Yang et al. 2008) during embryonic stem cells 
(ESCs) differentiation. Individual Bry+Kdr+ cells generated colonies capable of 
differentiating into cardiomyocytes, endothelial cells, and vascular smooth muscle 
cells (Kattman et al. 2006, Yang et al. 2008). Some colonies expressed SHF marker 
Isl1, whereas others were positive for Tbx5, a marker linked to FHF (Takeuchi et al. 
2003, Kattman et al. 2006, Yang et al. 2008). The next marker in the embryonic 
cardiovascular hierarchy, which may identify an early progenitor population that 
precedes the separation of the first and second heart lineages, is the transcription 
factor mesoderm posterior 1 (Mesp1). This factor seems to be important for the 
activation of the cardiogenic transcription factors: Nkx2.5, Gata-binding protein 4 
(Gata4), myocyte enhancer factor 2c (Mef2c), and Isl1 (Saga et al. 1999, Bondue et 
al. 2008). 
The expression of Nkx2.5 is indispensable for the development of ventricular 
cardiomyocytes and characterizes FHF- and SHF-derived cells committed to the 
cardiomyogenic fate (Figure 2) (Stanley et al. 2002, Wu et al. 2006). Another early 
marker, which may be used for sorting early cardiac progenitors, is stage-specific 
embryonic antigen-1 (Ssea-1) (Blin et al. 2010). Blin and colleagues have derived 
these cells from human ESCs and induced pluripotent stem cells (iPSCs), 
differentiating them into cardiomyocytes, smooth muscle cells, and endothelium (Blin 
et al. 2010). Recently, we were able to sort out a pure population of cells expressing 
Ssea-1 from human fetal hearts obtained from abortion material (Elsheikh et al. 
2013). Isolated cells expressed the pluripotent stem cell marker Oct4 as well as the 
key cardiac transcription factors Nkx2.5, Gata4, Isl1, and Tbx5. Besides expressing 
the markers of both FHF and SHF, these cells co-expressed the mesenchymal stromal 
cell markers. Furthermore, the expression of the cardiomyocyte-specific proteins, 
troponin T (TnT) and actin, was up-regulated following 5-azacytidine 
treatment (Elsheikh et al. 2013). 
Hcn4, voltage-gated ion channel, which is a hallmark of the conduction system and 
appears to specify the cells that predominantly differentiate into atrial and ventricular 
cardiomyocytes, was recently identified by Spater and colleagues as a specific marker 
of the FHF (Figure 2) (Spater et al. 2013). 
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The SHF develops from multi-potent cardiovascular progenitors characterized by the 
expression of the transcription factor Isl1 (Figure 2) (Cai et al. 2003, Laugwitz et al. 
2005, Moretti et al. 2006, Bu et al. 2009, Genead et al. 2010). SHF progenitors 
migrate from the pharyngeal mesoderm into the heart tube as it grows and undergoes 
looping (Cai et al. 2003, Genead et al. 2010). However, Isl1 protein has been detected 
already at the cardiac crescent stage, suggesting the possibility that Isl1 is expressed 
in FHF at a very early stage (Prall et al. 2007). In the OFT of the human fetal hearts 
at gestation week 9, Lui and colleagues identified an Isl1+ population of endothelial 
progenitors expressing VEGF-A receptors (Lui et al. 2013). Additionally, Vedantham 
et al. have recently demonstrated that Isl1 is a regulator of sino-atrial node 
development (Vedantham et al. 2015). Thus, in contrast to Hcn4, Isl1 expression may 
identify a transient progenitor state important for heart lineage diversification that 
rapidly converges into the vascular endothelial cell, myocardial and conduction 
system cell lineages, followed by down-regulation of Isl1 upon cardiomyocyte 
differentiation (Moretti et al. 2006, Genead et al. 2010). Recently, Jain et al. identified 
the earliest committed cardiomyocyte progenitor, cardiomyoblast, defined by the Hopx 
(homeobox gene) expression in cardiac progenitors from the SHF (Wnt-activated Isl+ 
progenitors) that are localized to the OFT and start expressing Hopx after down-
regulating Wnt (Jain et al. 2015). In the work by Genead et al, we characterized the 
distribution and electrophysiological properties of Isl1-positive progenitor cells in the 
first-trimester human fetal heart (Genead et al. 2010). At gestational weeks 5 to 10, 
Isl1+ cells were mainly detected in the OFT, but also in the atria and the right 
ventricle, with certain clusters co-expressing the cardiomyocyte marker TnT. 
Interestingly, most of the proliferating cells were Isl1-negative but TnT-positive, 
showing robust proliferative potential of fetal ventricular cardiomyocytes. When the 
cells were cultured as spontaneously beating cardiospheres, they expressed Nkx2.5 
and TnT, whereas Isl1 was detected only in a minority of cells (Genead et al. 2010). 
The embryonic proepicardial progenitor cells originating from the mesenchyme, 
express Tbx18 and Wilms tumor 1 (Wt1) (Figure 2), or semaphorin 3D (Sema3d) and 
scleraxis (Scx) (Cai et al. 2008, Zhou et al. 2008, Katz et al. 2012). These cells 
primarily differentiate into coronary smooth muscle and endothelial cells, but early in 
development, a subset of proepicardial progenitors express Isl1 and Nkx2.5 and may 
also differentiate into cardiomyocytes (Cai et al. 2008, Zhou et al. 2008). 
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Finally, the cranial neural crest cells (CNCs), which are involved in the development 
of heart valves and the parasympathetic innervation of the heart, are defined by the 
expression of the Pax3 marker (Figure 2) (Jiang et al. 2000). 
Even in the adult heart, a few resident Isl1+ cells can be found in the OFT, expressing 
TnT as a sign of cardiac commitment (Genead et al. 2012). Other proposed cardiac 
progenitors in the adult heart are c-Kit+, Sca-1+, platelet-derived growth factor 
receptor (Pdgfr)-α+, Ssea-1+, and side population cells respectively (Goodell et al. 
1997, Hierlihy et al. 2002, Beltrami et al. 2003, Oh et al. 2003, Bearzi et al. 2007, Ott 
et al. 2007, Chong et al. 2011, van Berlo et al. 2014, Santini et al. 2016). 
Characterization of these cells is based upon their surface markers and functional 
properties. 
The definitive proof of the existence of endogenous stem and progenitor cells in the 
adult heart would be of great value in the cardiac regenerative field. Nevertheless, 
establishing the relationship of these cells to the embryonic progenitors and arranging 
them within the heart development hierarchy is challenging, and it requires rigorous 
lineage-tracing strategies. 
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1.3 ENDOGENOUS CARDIAC STEM CELLS 
The cells with the properties of stem and progenitor cells detected in the adult heart 
are rare, comprising just 0.005-2% of all cardiac cells (Chong et al. 2014). These 
heterogeneous cell populations reside around vessels and among cardiac muscle 
fibers. Even if some studies suggest certain levels of plasticity of these residing stem 
cells, their in vivo function is less clear and their beneficial effects observed upon 
transplantation are most probably attributed to paracrine stimulation of angiogenesis 
and inhibition of apoptosis (Liang et al. 2014). Identifying the origin of the adult 
cardiac stem cells is critical in order to understand how cells with similar properties 
can be generated from other adult cell sources, which can be used for cardiac 
regeneration. 
 
 
Figure 2. Specification of the cardiac cell lineage. 
 
The stepwise commitment of pluripotent cells via various intermediate stages towards mature 
cardiac cell types within the heart during development. EPDCs, epicardium-derived cells; 
EMT, endothelial-to-mesenchymal transition; SAN, sino-atrial node; RBB, right bundle 
branch; LBB, left bundle branch; PF, Purkinje fibers; AV, atrioventricular. Reprinted with the 
permission from the publisher of (Spater et al. 2014) doi: 10.1242/dev.091538 
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1.3.1 c-Kit+ cardiac stem cells   
 
In 2003, a study by Beltrami et al indicated that c-Kit marks rare heterogeneous 
cardiac-resident adult stem cells, positive for Nkx2.5, Gata4, and Mef2c and negative 
for hematopoietic lineage markers (Lin
−
), and able to self-renew and differentiate into 
cardiomyocytes, smooth muscle cells, and endothelial cells both in vitro and after 
transplantation (Beltrami et al. 2003). Furthermore, c-Kit expression has been 
reported in cells of bone marrow origin, which enter the heart after injury (Fazel et al. 
2006, Cimini et al. 2007), in postnatal cardiomyocytes (Li et al. 2008, Tallini et al. 
2009), coronary endothelial cells and epicardial cells (Limana et al. 2007, Castaldo et 
al. 2008) as well as in dedifferentiated adult cardiomyocytes (Zhang et al. 2010). 
However, other groups have not been able to reproduce the multi-potent capacity of 
the c-Kit+ cells, but instead suggested a possible transient paracrine effect of these 
cells after transplantation (Keith and Bolli 2015). The initial positive results reported 
from the phase I: Stem Cell Infusion in Patients with Ischemic Cardiomyopathy 
(SCIPIO) trial (Bolli et al. 2011), where autologous culture-expanded c-Kit+ cells 
were delivered intracoronary, are now highly questioned (major concerns over trial’s 
experimental validity). A Phase II study investigating the Combination of 
Mesenchymal and c-Kit+ Cardiac Stem Cells as Regenerative Therapy for Heart 
Failure (CONCERT-HF) is presently underway (NCT02501811). Recently, a 
vigorous debate was initiated by the contrasting findings by Ellison et al (2013) and 
van Berlo et al (2014) (Ellison et al. 2013, van Berlo et al. 2014). This led Liu and 
colleagues to generate Kit-CreER mouse line for inducible lineage tracing (Liu et al. 
2016). The authors were able to follow Kit+ cells from the fetal up to adult heart and 
concluded that these cells are located within the endocardium and coronary 
endothelium, maintaining endothelial identity even after myocardial infarction. Also, 
only very rare cells were found to co‐express Kit and cardiomyocyte markers Nkx2.5 
or TnT in both healthy and injured hearts (Sultana et al. 2015, Liu et al. 2016).  
 
1.3.2 Isl1+ cardiac stem cells  
 
The LIM-homeodomain transcription factor Isl1, binds and controls cis-regulatory 
elements of the insulin gene (Karlsson et al. 1990). Isl1 is also expressed in cardiac 
mesodermal progenitors of the FHF and SHF, with the expression down regulated as 
these progenitors enter the heart and differentiate into cardiac lineages (Cai et al. 
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2003, Prall et al. 2007, Peng et al. 2013). A modest expression has also been detected 
in cardiac neural crest cells by lineage tracing (Engleka et al. 2012). Isl1 deletion 
affects the survival and proliferation of heart progenitors as well as their deployment 
to the forming heart tube (Cai et al. 2003, Laugwitz et al. 2005).  It has been 
suggested that Isl1+ cells persist in rodents beyond early heart development into 
neonatal and adult life, distributed in a pattern that is consistent with a SHF origin 
(Bu et al. 2009, Genead et al. 2010). At fetal stages, the majority of the Isl1+ cells 
co‐expressed the cardiomyocyte marker TnT, suggesting a cardioblast identity, and 
only few of these cells were proliferating (Genead et al. 2010). Human fetal Isl1+ 
cardiovascular progenitors were shown to give rise to the cardiomyocyte, smooth 
muscle and endothelial cell lineages (Bu et al. 2009). The Isl1+ cells are rare in the 
adult heart, and in mice they are largely confined to the sino-atrial node (Weinberger 
et al. 2012). It is still unclear if Isl1+ cells represent a compelling stem cell 
population in the adult heart that can be activated for cardiac repair. However, human 
and mouse ESCs bearing Isl1 reporters, expressing both Isl1 and Nkx2.5, showed 
trilineage differentiation potential that could be maintained on feeder layers 
expressing Wnt3a (Qyang et al. 2007). These findings suggest that cardiac 
progenitors marked by Isl1 might be suitable for cell therapy after cardiac injury.  
Furthermore, injection of naked DNA encoding Isl1 into the peri-infarct region in 
mice subjected to myocardial infarction increased left ventricular function and tissue 
revascularization and reduced fibrosis (Barzelay et al. 2012). Isl1 has also been 
identified as a regulator of EMT in epicardial cells (Bronnum et al. 2013), suggesting 
a promotion of stem cell characteristics in epicardium as another possible 
regenerative target.  
 
1.3.3 Pdgfrα+ cardiac mesenchymal progenitor cells 
 
A mesenchymal stromal cell-like population has recently been identified in the adult 
heart expressing both Pdgfrα and Sca1. Based on the ability of these cells to form 
clonal colonies, this highly heterogeneous population was named cardiac colony-
forming units fibroblast (cCFU-F) (Chong et al. 2011, Noseda et al. 2015). In the 
embryo, Pdgfrα is expressed in the early cardiac mesoderm (Chong et al. 2011, 
Kattman et al. 2011) and in the cardiac neural crest (Hoch and Soriano 2003). In 
Pdgfrα knockout mice, defects affecting the OFT, the septum, the chambers and the 
coronary vessels were observed (Soriano 1997). Epicardial specific Pdgfrα knockout 
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mice show defective EMT and death of cardiac stromal fibroblasts (Smith et al. 
2011). In the fetal heart, Pdgfrα marks the proepicardial and epicardial-derived 
cardiac stromal cells as they undergo EMT to enter the interstitial spaces of the 
chambers as well as the valves (Chong et al. 2011). In the adult heart, single-cell 
expression profiling confirmed that the Sca1
+
/Pdgfrα+ fraction of cardiac interstitial 
cells probably derives from the epicardium and can be detected in the interstitium and 
the perivascular niche (Chong et al. 2011, Chong et al. 2013). Certain colonies were 
positive for Gata4, Tbx5, and Mef2c, suggesting a cardiac lineage commitment 
(Furtado et al. 2014, Noseda et al. 2015). Cultured cCFU-Fs show clonogenicity, 
long-term self-renewal, and multi-lineage differentiation in vitro and in vivo (Chong 
et al. 2011, Noseda et al. 2015).  cCFU-F in both healthy and infarcted hearts were 
shown to have their lineage origins in the proepicardium and epicardium (Zhou et al. 
2008, Chong et al. 2011, Noseda et al. 2015). As such, the cardiac Pdgfrα+ stromal 
cell fraction may share properties with the epicardium and other mesothelial cells that 
give rise to stromal and smooth muscle lineages during development (Rinkevich et al. 
2012). Uchida and colleagues used CRE lineage tracing on a heterogeneous adult 
cardiac interstitial population expressing Sca1 (Uchida et al. 2013), and demonstrated 
that these cells are unipotent progenitors that differentiate mostly into smooth muscle 
cells, but also coronary endothelial cells and to some extent cardiomyocytes. 
However, recently, Sommariva and colleagues reported that cardiac MSCs might also 
be a source of adipocytes and contribute to fibrosis in arrhythmogenic 
cardiomyopathy (Sommariva et al. 2016).  Furthermore, Gli1, the effector of 
hedgehog signaling, is thought to mark a population of Pdgfrα+ perivascular MSCs, 
which has been related to fibrosis (Kramann et al. 2015). The lineage tracing of these 
cells in hypertensive and pressure overload models of cardiac fibrosis showed that 
they differentiate into myofibroblasts expressing smooth muscle α-actin (SMA), 
where Gli1+/SMA+ cells were abundant in the scared area after myocardial infarction 
(Kramann et al. 2015). Cardiac stromal cells might also act as sentinels of cardiac 
stress and mediate cellular communication between cardiomyocytes, immune cells 
and other endogenous progenitors through paracrine mechanisms (Ieda et al. 2009, 
Amoah et al. 2015). However, additional studies are necessary in order to get better 
insight into the cardiac interstitial lineage hierarchy and cellular functions in health 
and disease (Furtado et al. 2016).  
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1.4 PATHWAYS CONTROLLING SPECIFICATION AND DIFFERENTIATION 
OF EMBRYONIC CARDIAC STEM CELLS 
 
The process of cardiac lineage specification and differentiation is primarily controlled 
by activating or inhibiting the Activin A, bone morphogenetic protein (BMP), Wnt, 
Notch, and FGF signaling networks, as well as regulating key cardiac transcriptional 
factors such as Nkx2.5, Gata4, Tbx5, and the chromatin remodeling protein 
SMARCD3 (Marvin et al. 2001, Harvey 2002, Srivastava 2006, Lopez-Sanchez and 
Garcia-Martinez 2011, Noseda et al. 2011, Kelly et al. 2014, Spater et al. 2014). The 
commitment of the Bry+ mesodermal progenitors toward a cardiogenic fate requires 
the inhibition of canonical and activation of non‐canonical Wnt signaling (Gessert 
and Kuhl 2010). The expansion and differentiation of Nkx2.5 and Isl1+ cardiac 
progenitors is also dependent on canonical Wnt signaling, and a sequential induction 
and inhibition of this pathway has led to the development of a robust cardiomyocyte 
differentiation protocol from embryonic and induced pluripotent stem cells (Lian et 
al. 2012). The Notch, IGF, Sonic Hedgehog, and Hippo signaling pathways have also 
emerged as important regulators in cardiovasculogenesis, and disturbances in these 
pathways cause a broad spectrum of cardiac anomalies (Xie et al. 2012). 
Besides the transcriptional signals, which are critical for the activation of cardiac 
genes, a number of recent reports highlight posttranscriptional regulation by small, 
noncoding micro-RNAs (miRNAs) as the emerging novel regulator of cardiogenesis 
and a tool in enhancing the endogenous regenerative potential of the heart (Cordes 
and Srivastava 2009, Aguirre et al. 2014). miR-1 and -499 are shown to be promising 
candidates in the modulation of cell specification towards myogenic differentiation 
(Sluijter et al. 2010). 
Another signaling system involved in cardiogenesis and final development toward a 
functioning organ is the ephrin/Eph family of tyrosine kinase receptors and ligands, 
responding to mesodermal induction signals (Wang et al. 2004), influencing cell 
migration, neural cell migration, and cell-to-cell interaction during 
embryogenesis (Brantley-Sieders and Chen 2004). Furthermore, EphB2 and B4 are 
distinguished features of arterial and venous endothelial cells (Wang et al. 1998), and 
the lack of or defect expression of these receptors cause severe cardiovascular 
malformations and defect trabeculation of the ventricles due to poor cell-to-cell 
interaction between the endothelium and the adjacent tissue during embryogenesis. In 
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addition, the ErbB–neuregulin signaling system plays an essential role in 
cardiogenesis. Defect expression of the ErbB family of tyrosine kinase receptors 
(ErbB2/B4) during embryogenesis causes cardiac malformations and defects of the 
left ventricular trabeculation (Ozcelik et al. 2002). Neuregulin-1 activation of the 
ErbB4 receptor induces a cascade of intracellular transduction upon stimulation with 
the ErbB4 ligand neuregulin-1β. Furthermore, neuregulin-1β activation of the ErbB4 
receptor is shown to enhance cardiomyocyte differentiation in ESCs (Wang et al. 
2009, Hao et al. 2014, Iglesias-Garcia et al. 2015). 
The first efforts to differentiate pluripotent stem cells (PSCs) into cardiomyocytes 
used a strategy of embryoid body (EB) formation, in which the cells differentiate 
spontaneously into different cellular lineages, yielding a low percentage of 
cardiomyocytes. Further differentiation protocols were developed, based on 
increasing insight in the dynamics of signaling pathways that control cardiac 
development in vivo, and succeeded to efficiently generate more than 50% pure 
populations of cardiomyocyte from PSCs (Laflamme et al. 2007, Yang et al. 2008, 
Kattman et al. 2011, Lian et al. 2012). 
Finally, purification methods have been developed based on separation of cells 
expressing cardiomyocyte specific traits, which yield up to 98% pure populations of 
cardiomyocytes. These include the expression of the signal regulatory protein alpha 
(SIRPA) (Dubois et al. 2011) and differences in cardiomyocyte glucose metabolism 
versus lactate metabolism in non‐cardiomyocytes (Tohyama et al. 2013). A recent 
study has demonstrated the feasibility to scale up production of human ESC-derived 
cardiomyocytes, which could integrate after transplantation into non‐human primate 
hearts (Chong et al. 2014). 
 
1.5 POSTNATAL CARDIOMYOGENESIS IN MAMMALIAN AND 
NON‐MAMMALIAN VERTEBRATE SPECIES 
 
Our present understanding of cardiac regeneration has been mainly based on studies 
in the newt and the zebrafish, which are able to fully regenerate hearts after 
amputation of up to 20% of the ventricle (Laube et al. 2006, Jopling et al. 2010). 
Upon injury, cardiomyocytes of the newt and the zebrafish dedifferentiate into 
progenitor-like cells, characterized by the disassembly of their sarcomeric structure 
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that reenter the cell cycle and subsequently redifferentiate into mature 
cardiomyocytes (Laube et al. 2006, Jopling et al. 2010). Additionally, Lepilina and 
colleagues suggested that a pool of undifferentiated progenitors is the basis of 
zebrafish cardiac regeneration (Lepilina et al. 2006). Using a genetic fate-mapping 
strategy, Zhang and coworkers could demonstrate that atrial cardiomyocytes 
contribute to ventricular regeneration through a step of dedifferentiation (Zhang et al. 
2013). Following targeted destruction of the ventricle of the zebrafish, atrial 
cardiomyocytes adjacent to the atrioventricular canal underwent a dedifferentiation 
process and started to reexpress the cardiac progenitor markers Gata4, Hand2, Nkx2-
5, Tbx5, and Tbx20, while proliferating and migrating into the injured ventricle. 
Moreover, SHF progenitors, resident near the OFT, also seemed to contribute to the 
ventricular cardiomyocytes. These findings indicate that non‐mammalian vertebrate 
species regenerate ventricular cardiomyocytes through both dedifferentiation and 
proliferation of cardiomyocytes and, most probably, also by the activation of resident 
cardiac progenitors. 
The regenerative capacity of the mammalian heart is very limited, as cardiomyocytes 
withdraw from the cell cycle, and become binucleated early on in the neonatal 
period (Li et al. 1996). In mice, especially in the neonatal period, a certain turnover of 
cardiomyocytes has been shown through the proliferation of already-existing 
cardiomyocytes (Porrello et al. 2011, Senyo et al. 2013). Porrello and colleagues have 
demonstrated that the mouse heart can fully regenerate if amputation of the 
ventricular apex occurs on the first neonatal day. This remarkable repair seems to be 
achieved through a mechanism comparable to that of the zebrafish, namely through 
dedifferentiation and proliferation of existing cardiomyocytes. However, in contrast 
to the newt and the zebrafish that retain regenerative capacity throughout life, in mice 
this initial robust regenerative potential is rapidly lost already within the first 
postnatal week (Porrello et al. 2011). Intriguingly, one common trait of the zebrafish 
and the mammalian fetal heart is that they both reside in a hypoxic environment.  
The neonatal mammalian heart is an excellent model to study important factors 
involved in mammalian regeneration. Meis1, for example, was shown to be a critical 
regulator of the cardiomyocyte cell cycle in neonatal mice, where Meis1 deletion 
increased the postnatal proliferative window of cardiomyocytes and reactivated their 
entry into mitosis (Mahmoud et al. 2013). Others used the regenerating neonatal 
mouse heart to identify a regulator of cell cycle entry, interleukin 13 (O'Meara et al. 
2015). Recently, Mahmoud et al also demonstrated that pharmacological cholinergic 
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nerve inhibition impairs neonatal mice heart regeneration, which could be rescued by 
administration of neuregulin-1 and nerve growth factor (Mahmoud et al. 2015). Using 
a genetic approach to label neural crest lineages, White et al similarly demonstrated 
that sympathetic denervation with 6-OHDA inhibited neonatal heart regeneration 
(White et al. 2015).  
However, the primary post-natal event that results in cardiomyocyte cell-cycle arrest 
still needs to be identified. One very interesting hypothesis is that transition to the 
oxygen rich postnatal and the subsequent increase in oxidative metabolism is the 
upstream signal that triggers cell cycle exit of cardiomyocytes shortly after birth 
(Puente et al. 2014). Indeed, recently, Puente et al. demonstrated that postnatal 
hypoxemia, ROS scavenging, or inhibition of DNA damage response (DDR) could all 
prolong the postnatal proliferative window of cardiomyocytes, while hyperoxemia 
and ROS generators shorten it (Puente et al. 2014). 
During adolescence, the proliferation of cardiomyocytes is reduced, except for the 
thyroid hormone surge at postnatal day 15, which activates the IGF-1/IGF1-R/AKT 
pathway initiating a proliferative burst with a concomitant increase in the number of 
cardiomyocytes with about 40% (Naqvi et al. 2014). However, Alkass et al, using 
design-based stereology, were not able to confirm these findings and concluded 
instead that the number of cardiomyocytes is set within the first postnatal week, 
followed by two waves of non-replicative DNA synthesis (Alkass et al. 2015). 
In humans, Bergmann and colleagues performed carbon-14 birth-dating studies 
demonstrating that fewer than 50% of cardiomyocytes are replaced over an entire life 
span and that the rate of replacement declines with age (Figure 3) (Bergmann et al. 
2009, Bergmann et al. 2015). Several recent reports confirm this finding showing a 
low (<1% per year) turnover rate in the adult mammalian heart (Mollova et al. 2013, 
Senyo et al. 2013, Naqvi et al. 2014, Bergmann et al. 2015).  
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Even if there is no evidence for thyroid hormone-induced proliferation of 
cardiomyocytes in early adolescence of humans, karyokinesis, division of the 
nucleus, was observed throughout life, whereas division of the cell cytoplasm 
(cytokinesis) could not be detected in human hearts after 20 years of life (Mollova et 
al. 2013). From these human studies, we can draw the conclusion that new 
cardiomyocytes are generated in the postnatal heart but at a slow rate, and that the 
cellular origin of these cells is still unknown. Importantly, as both Bergmann and 
Mollova performed studies on presumably normal hearts from individuals without a 
known history of cardiac disease, the possible increase in the cardiomyocyte turnover 
rate upon injury is not excluded, as shown in mice subjected to myocardial 
damage (Senyo et al. 2013). 
As mentioned previously, the generation of morphologically and functionally 
different cardiac cells during embryogenesis is achieved by EMT (Kovacic et al. 
2012). EMT is not only associated with wound healing and organ repair, but also with 
fibrosis (Kalluri 2009, Kovacic et al. 2012). In this regard, a significant difference 
 
Figure 3. The turnover of cardiomyocytes in humans 
 
A comprehensive analysis of the cell generation and turnover rates shows that cardiomyocytes 
have a very low turnover rate throughout the human lifespan, with a low turnover rate. 
Endothelial and mesenchymal cells are exchanged at a high rate. Reprinted with the permission 
from the publisher of (Bergmann et al. 2015) http://dx.doi.org/10.1016/j.cell.2015.05.026 
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between the embryonic and the adult environment is the role of the immune system. 
Embryos develop in an immune-permissive environment, in contrast with adult 
tissues in which a robust inflammatory reaction could preclude stem cell 
differentiation leading to scar formation instead of tissue repair (Santini et al. 2016). 
 
1.6 POTENTIAL FOR ENDOGENOUS REGENERATION IN THE ADULT 
HEART  
 
1.6.1 Contribution of progenitor cells to heart regeneration 
 
As described in the previous section, during aging, the renewal of cardiomyocytes in 
the mammalian heart is mainly due to the proliferation of existing cardiomyocytes 
(Senyo et al. 2013, Naqvi et al. 2014), with some contribution of cardiac progenitors. 
But what happens after myocardial injury? Hsieh and colleagues were the first to 
demonstrate the role of cardiac progenitors for myocardial regeneration after 
myocardial injury (Hsieh et al. 2007). They generated a double-transgenic 
MerCreMer-ZEG mouse model in order to track the fate of cardiomyocytes in a 
“pulse-chase” fashion. In this transgenic mouse model, the administration of 4-OH-
tamoxifen (pulse) induced β-galactosidase (β-gal) to be replaced by green fluorescent 
protein (GFP) exclusively in cardiomyocytes expressing α-myosin heavy chain 
(Myh6). Following myocardial infarction or after pressure overload, the ratio between 
GFP+ and β-gal+ cardiomyocytes was significantly reduced in the infarction border 
zone and in the pressure-overloaded myocardium, indicating a contribution of cardiac 
progenitor cells (GFP
−
 cells) to the cardiomyocyte pool. By contrast, if 
cardiomyocyte replenishment was done through the proliferation of adult 
cardiomyocytes, the percentage of GFP+ cells would have been relatively unchanged. 
In an attempt to further confirm that cardiac progenitors contributed to cardiomyocyte 
renewal after myocardial injury, c-Kit mRNA was quantitatively measured in the 
infarcted area up to 7 days post injury, which demonstrated a significant increase of 
c-Kit mRNA only in the infarcted areas (Hsieh et al. 2007). 
These findings are supported by a report by Genead et al. (Genead et al. 2012), where 
myocardial infarction but especially ischemia–reperfusion injury but also induced a 
generalized up-regulation of c-Kit, which also correlated with the concomitant up-
regulation of the early cardiomyocyte marker Nkx2.5 (Genead et al. 2012). Ischemia–
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reperfusion injury also caused a focal up-regulation of Isl1 RNA in the OFT and peri-
ischemic regions. Similarly, Smart and colleagues have been able to demonstrate that 
in adult mice hearts, the expression of the epicardial progenitor markers Wt1 and 
Tbx18 was significantly increased 7 days after myocardial infarction (Smart et al. 
2011). 
In another study by Ellison and colleagues (Ellison et al. 2013), c-Kit+ cardiac stem 
cells were reported as the primary source for regeneration of cardiomyocytes after 
myocardial ischemia. Using a diffuse myocardial infarction model in rats, the authors 
demonstrated that myocardial ischemia induced the proliferation of small 
mononucleated cardiomyocytes starting at day 3, and during the following 25 days 
there was a significant increase in the number and size of cardiomyocytes (Ellison et 
al. 2013). In vivo genetic cell-fate-mapping studies, tagging the c-Kit+ cardiac stem 
cells, demonstrated that the majority of the newly formed cardiomyocytes after 
myocardial ischemia originated from these progenitors. This study, however, has 
been highly questioned after the contrasting report by van Berlo et al. (van Berlo et 
al. 2014), who generated transgenic mice in which the c-Kit locus was used for 
lineage tracing. According to this study, the contribution of c-Kit+ cells to 
cardiomyocyte renewal in aging and injured myocardium was very low, and it should 
have no functional implication. Similarly, with five independently derived lineage 
tracing mouse models, Sultana et al found that c-Kit+ cells generate less than 0.05% 
cardiomyocytes during development, aging, or after a myocardial infarction and 
,instead, represent a subpopulation of endothelial cells (Sultana et al. 2015).   
There also seem to be an age-related heterogeneity among c-Kit+ cells. After 
myocardial infarction induction in neonate mice hearts, the proliferating c-Kit+ cells 
adopted both a myogenic and vascular phenotype, whereas infarction of the adult 
heart resulted in a modest c-Kit+ cell proliferation, and a vascular fate decision (Jesty 
et al. 2012). This may indicate that c-Kit+ cells represent different subpopulations 
where the real multi-potent cardiovascular progenitor cells disappear with age. 
 
1.6.2 Direct Lineage Conversion 
 
In 1987, a seminal discovery was made showing that ectopic expression of a single 
skeletal muscle gene, Myod1, could convert fibroblasts into skeletal muscle cells 
(Davis et al. 1987). Recently, local delivery of the three transcription factors (Gata4, 
Mef2c, and Tbx5; together known as GMT) into the infarcted area of mice hearts 
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induced reprogramming of the cardiac fibroblasts into functional cardiomyocytes 
(Qian et al. 2012).  
Addition of Hand2 to these three factors (GHMT) increased the direct 
reprogramming efficiency from approximately 7% to 20% (Song et al. 2012). To 
translate this direct reprogramming system from mouse to human, it was discovered 
that Myocd was additionally required (Nam et al. 2013). Polycistronic vectors were 
used to express different ratios of the GMT factors and found that, if Mef2c 
expression is increased compared with Gata4 and Tbx5, then reprogramming 
efficiency of fibroblasts into cardiomyocytes could be increased five-fold (Wang et 
al. 2015).  
1.7 THE ROLE OF CASPASES IN CARDIAC DIFFERENTIATION 
 
The mechanism by which heart injury modulates the activation of cardiac stem cells 
is still poorly understood, where several studies suggest a role of released paracrine 
factors from cardiomyocytes, changes in the metabolic environment, exosome 
signaling, pro-inflammatory cytokines as well as recruitment of bone marrow-derived 
MSCs (BM-MSCs) (Steinhauser and Lee 2011). Still, an unresolved question is 
whether different types of injuries with diverse effects on the heart, can all converge 
into a common cardiac progenitor cell response mediated through a common stress-
activated signaling pathway (Fernando and Megeney 2007, Abdul-Ghani and 
Megeney 2008).  
Caspases, a family of cysteinyl-aspartate-specific proteases, are master regulators of 
apoptosis and their activation is considered mandatory to initiate and execute 
programmed cell death (Nicholson et al. 1995, Cohen 1997). However, recent 
findings suggest a number of non-apoptotic roles of caspases (Figure 4), like self-
renewal and differentiation of ESCs (Fujita et al. 2008), hematopoietic stem cells 
(Janzen et al. 2008) as well as differentiation of skeletal muscle and neurons 
(Fernando et al. 2002, Fernando et al. 2005). Experimental activation of these 
proteases can be used for unraveling cell fate decisions beyond programmed cell 
death. For instance, transient caspase 3-activation is required for the differentiation of 
various cell types, including neural precursor cells, hematopoietic cells and skeletal 
myoblasts (Fernando et al. 2002, Fernando et al. 2005, Fernando and Megeney 2007, 
Janzen et al. 2008, Larsen et al. 2010). In mESC cells, inhibition of caspases 3 and 8 
impairs cardiomyocyte differentiation (Hunter et al. 2007, Abdul-Ghani et al. 2011), 
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while doxycycline-mediated activation of caspase 3 stimulates differentiation and at 
the same time decreases the expression levels of Nanog and Oct4 (Fujita et al. 2008). 
A recent report by Akbari-Birgani et al. suggests that delay in the release of 
cytochrome C, apoptosome formation and caspase 3- activation discriminates 
apoptosis from differentiation in mouse ESCs (Akbari-Birgani et al. 2014). It has also 
been proposed that apoptosis and muscle differentiation induce similar cytoskeletal 
and phenotypical changes, for example actin fiber disassembly and reorganization, 
and thus share activation of similar molecular pathways (Fernando et al. 2002, 
Murray et al. 2008). A mechanism of action by which active caspase 3 induces 
cardiac differentiation might be through cleavage and activation of mitogen-activated 
protein kinase (MAPK) signaling cascades (MST1/MKK6/p38) (Fernando et al. 
2002). Downstream components of these cascades up-regulate Mef2a and c factors, 
known to be important for cardiomyocyte differentiation (McKinsey et al. 2000). In 
the work by Abdul-Ghani et al. (Abdul-Ghani et al. 2011), the authors demonstrated 
that caspases mediate cardiac differentiation through their proteolytic cleavage of β-
catenin, leading to a loss of canonical Wnt signaling activity (Steinhusen et al. 2000).   
Recently, Wang et al demonstrated that skeletal muscle dedifferentiation during newt 
limb regeneration depends on a programmed cell death response (Wang et al. 2015). 
The authors were able to derive a proliferating progeny from differentiated, 
multinucleated muscle cells by first inducing and subsequently intercepting a 
programmed cell death response (Wang et al. 2015). Since the dedifferentiation of 
existing, mature cardiomyocytes was proposed as a mechanism of heart regeneration in 
both zebrafish and neonatal mice (Jopling et al. 2010, Porrello et al. 2011), these 
findings suggest that manipulation of apoptotic mechanisms might be an attractive 
strategy to boost cardiac endogenous regenerative potential in response to injury. 
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1.8 THE ROLE OF METABOLISM IN DEVELOPMENT AND 
CARDIOMYOCYTE DIFFERENTIATION 
 
Rather than being only a consequence of the energy requirements of a cell, the 
metabolism is now also believed to play an active role in determining cell fate and 
regulating cell renewal and differentiation. This occurs through a shift in balance from 
glycolysis to oxidative phosphorylation (OxPhos) during maturation of stem cells, and 
vice versa during the reprogramming to pluripotency (Figure 5) (Folmes et al. 2011, 
Varum et al. 2011, Folmes and Terzic 2016). Consequently, the differentiation is 
characterized by cytosolic elongated and cristae-rich mitochondria, while 
reprogramming induces regression into a few spherical and cristae-poor perinuclear 
mitochondria (Folmes et al. 2011, Varum et al. 2011, Folmes and Terzic 2016). Studies 
of metabolism in various stem cell populations have identified tissue- and cell-specific 
metabolic pathways that are tightly regulated during development (Shyh-Chang et al. 
2013, Takubo et al. 2013).  
Wnt-signaling controls many biological processes including self-renewal and 
differentiation of cardiac progenitors. Moreover, regulation of the cellular metabolism 
may represent a general mechanism contributing to the wide-range of functions 
controlled by Wnt-proteins. For instance, it is suggested that Wnt3a induces transition 
Figure 4. Emerging roles of mammalian caspases. 
Caspases have been shown to play a role in cell proliferation, differentiation and apoptosis as 
well as cytokine processing during inflammation. Reprinted with the permission from the 
publisher of (Fadeel et al. 2000) 
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to aerobic glycolysis, known as the Warburg effect, by increasing the levels of key 
glycolytic enzymes (Esen et al. 2013). This metabolic regulation requires Lrp5 but not 
β-catenin, and is mediated by mTORC2-AKT signaling (Esen et al. 2013). A similar 
metabolic switch occurs in the earliest developmental stage from highly active 
mitochondria in naive (blastocyst ESCs) to highly glycolytic state in primed ESCs (in 
the post-implantation epiblast) (Figure 5) (Zhou et al. 2012, Takashima et al. 2014, 
Sperber et al. 2015). As development proceeds, the primed state, which mainly relies 
on glycolysis as energy source, rapidly changes to highly active OxPhos when the cells 
begin to differentiate. 
Studies on undifferentiated adult BM-MCSs have shown that these cells rely on 
glycolysis for energy supply, while activating the mitochondrial processing through 
OxPhos during differentiation (Chen et al. 2008). A number of transcriptional and 
signaling pathways converge to regulate glycolysis, where the hypoxia-inducible factor 
(HIF) pathways are the best characterized (Papandreou et al. 2006, Goda and Kanai 
2012, Semenza 2012). The metabolic switch from OxPhos to glycolysis occurs very 
early in the reprogramming process and requires both Hif1 and Hif2 proteins, each 
independently and stage-specifically (Mathieu et al. 2014, Prigione et al. 2014). The 
emerging role of hypoxia and the Hif in the acquisition of stemness is an example of 
metabolic context in cell fate (Zhou et al. 2012, Mathieu et al. 2013, Shyh-Chang et al. 
2013, Mathieu et al. 2014, Shiraki et al. 2014). Through the stabilization of the Hif 
activity, stem cells acquire a metabolic profile (Zhou et al. 2012, Mathieu et al. 2014) 
that may be determinative for stemness (Zhou et al. 2012, Mathieu et al. 2014) and 
allows for a highly proliferative state. Indeed, hypoxia can induce the reversal of the 
early steps in human ESC differentiation (Mathieu et al. 2013).  
However, the dependency of stem cells on glycolysis to produce ATP could also reflect 
an adaptation to low oxygen tensions in vivo, since hypoxia is a key feature of the stem 
cell niche (Suda et al. 2011). Glycolysis is optimal to fuel lower energetic demands of 
quiescent MSCs residing within niches with low oxygen, and limits oxidative 
metabolism-dependent generation of potentially damaging reactive oxygen species 
(ROS) (Mohyeldin et al. 2010, Suda et al. 2011, Ito and Suda 2014, Perales-Clemente 
et al. 2014). Besides BM-MSCs, several other tissue specific adult stem cells including 
long-term hematopoietic stem cells (Tothova et al. 2007) and neural stem cells (Renault 
et al. 2009) reside within in vivo niches with low oxygen tensions. These niches are 
suggested to maintain cells in a glycolytic quiescent state to ensure their long-term self-
renewal by limiting the generation of ROS and subsequent ROS-induced cellular 
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damage (Ito and Suda 2014). Another consideration is that glycolysis is a preferred 
method of ATP production in proliferating cells and oxidative stress induced 
senescence has been shown to limit the expansion of MSCs in normoxic conditions.  
 
1.9.1 Cardiac metabolic transitions during differentiation and maturation 
 
An important cardiac regenerative strategy might be to deliver cardiogenic MSCs, 
where the studies of cellular metabolomics may provide knowledge about the cells that 
have the highest propensity to differentiate into functional cardiomyocytes. 
Cardiomyocytes undergo several changes in order to increase their metabolic capacity 
with age. One of the most significant metabolic changes in cardiomyocytes is the 
transition from anaerobic to oxidative metabolism (Sartiani et al. 2007).  
In the fetal heart, cardiomyocyte progenitors preferably use lactate to fuel OxPhos 
(Werner and Sicard 1987). The fetal heart is adapted to a low oxygen environment and 
highly dependent on glycolysis to produce ATP (Lopaschuk and Jaswal 2010). Since 
lactate is plentiful in the fetal heart, fetal tissue will also produce a large part of its ATP 
via lactate oxidation.  
After birth, the heart undergoes a period of massive cellular growth while adapting to 
an increased workload, and its energy demands cannot longer be satisfied via glucose 
and lactate oxidation alone (Lai et al. 2008). There is also a concomitant increase in 
circulating levels of free fatty acids that mediates a switch from predominant glycolysis 
in immature cardiomyocytes to predominant OxPhos as energy source in the postnatal 
heart (Kolwicz et al. 2013). As lactate levels fall during development, the cardiac tissue 
changes from being mainly dependent on lactate oxidation, to utilize fatty acids as 
primary fuel source (Kolwicz et al. 2013). Changes in metabolic substrates are coupled 
with mitochondrial reorganization in order to more efficiently power beating 
cardiomyocytes. As cardiomyocytes mature, the number of mitochondria in each cell 
increases and these mitochondria have highly developed cristae and are more densely 
packed than in young cardiomyocytes (Legato 1979). The adult cardiomyocytes need a 
high metabolic rate to fulfill a constant demand for ATP to power continual contractile 
activity (Schonfeld et al. 1996). Under normal physiological conditions cardiac ATP is 
predominantly generated by OxPhos using fatty acids as a substrate (Figure 5). 
However, mature cardiomyoctes have a very limited ability to store high energy 
phosphates (Lopaschuk and Jaswal 2010). A small amount of ATP is generated via 
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anaerobic glycolysis within the cytosol, and is of critical importance when 
mitochondrial function is limited (Taegtmeyer et al. 2004, Taegtmeyer et al. 2010). 
This switch in metabolic substrate and reorganization of mitochondria are key 
components of cardiomyocyte development. When the respiratory chain function is 
experimentally disrupted during cardiac differentiation of stem cells, it compromises 
the ability of cardiomyocytes to reorganize their mitochondria and switch their 
metabolic profiles, resulting in impaired contractile machinery (Chung et al. 2007). It 
has also been suggested that the switch in metabolic profile is a potential regulator of 
cardiomyocyte maturation. Thus, unrevealing the mechanisms that contribute to 
changes in cardiac progenitors metabolic profile might lead to better understanding of 
cardiomyocyte maturation. 
Recent work has identified a number of factors that regulate cardiomyocyte metabolic 
maturation, acting both inter- and intra-cellular. It was shown that the let-7 family of 
microRNAs works endogenously in cardiomyocytes to accelerate maturation, largely 
through a significant impact on cardiomyocyte metabolism (Kuppusamy et al. 2015). 
The let-7 miRNA family target genes are involved in the PI3/AKT/insulin pathway.  
Recently, Puente et al. suggested that the increase in environmental oxygen and the 
subsequent up-regulation of oxidative metabolism is the upstream signal that triggers 
cell cycle exit of cardiomyocytes shortly after birth (Puente et al. 2014). To further 
address this hypothesis, Kimura et al. generated a transgenic mouse expressing a 
chimaeric protein in which the oxygen-dependent degradation (ODD) domain of Hif-
1α is fused to the tamoxifen-inducible CreERT2 recombinase and were able to identify 
a rare population of hypoxic cardiomyocytes in the adult mice (Kimura et al. 2015). 
Interestingly, these hypoxic cardiomyocytes were smaller in size, mononucleated and 
displayed lower oxidative DNA damage, resembling the proliferative neonatal 
cardiomyocytes, and finally, contributed to new cardiomyocyte formation in the adult 
heart (Kimura et al. 2015).  
Furthermore, Principal Component Analysis (PCA) on RNA-seq of human adult and 
fetal hearts, as well as on 20-day and 1-year old cardiomyocytes derived from H7 
hESCs, showed that among the top genes that contributes to the separation of fetal 
versus adult samples there are many genes related to metabolism and OxPhos (Ellen 
Kreipke et al. 2016). Among the top metabolic genes, the glucose transporters (HEPH 
and SLC7A/SLC2A3) were mainly upregulated in the fetal but not the adult 
cardiomyocytes (Ellen Kreipke et al. 2016). Similarly, Nicotinamide N-
Methyltransferase (NNMT) was upregulated in more mature cardiomyocytes compared 
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to fetal-like samples (Ellen Kreipke et al. 2016). While it was shown that NNMT 
represses Wnt and activates the HIF pathway in primed hESCs by controlling substrate 
availability for H3K27me3 histone methylation (Sperber et al. 2015), its role in 
cardiomyocyte maturation remains to be identified. 
Interestingly, one of the hallmarks of pathological hypertrophy and heart failure is a re-
expression of the fetal gene program. Common fetal genes that are upregulated include: 
atrial natriuretic factor (Anf), brain natriuretic peptide (BNP), and α-myosin heavy 
chain (αMHC). From a metabolic standpoint, there is also a reversion to a fetal-like 
metabolic state. However, it is not a complete reversion. As previously discussed, the 
fetal and neonatal heart rely on glycolysis as a source of energy, and thereby a related 
increased activity of glycolytic pathway associated enzymes (Fisher et al. 1980). 
Following birth, there is a 10-fold increase in fatty acid oxidation along with a decrease 
in glycolytic rates (Itoi and Lopaschuk 1993). In some forms of heart failure, this 
pattern is reversed (Allard et al. 1994, Nascimben et al. 2004) with either no change or 
a decrease in glucose oxidation (Leong et al. 2002, Kolwicz et al. 2013). 
Post-ischemic myocardium is characterized by hypoxia, inflammation, and oxidative 
stress (Milano et al. 2004, Zhu et al. 2006, Garedew and Moncada 2008, Ong and 
Gustafsson 2012), all of which induce dysfunction of mitochondria, the gatekeepers 
of cell survival (Ott et al. 2007). The hypoxic environment of the myocardium 
activates HIF1, which, in turn, activates transcriptional programs to alleviate the 
effects of the low oxygenation, thus stimulating myocardial angiogenesis, 
cardiomyocyte growth, and reprogramming of metabolism (Semenza 2014). 
However, in the case of continued pathological stress, this compensatory mechanisms 
ability to rescue the hypoxic environment becomes detrimental.  
Characterization of the metabolism of MSCs under different oxygenation conditions 
would, thus, provide critical insight for identifying pathways important for reducing 
cell vulnerability to the hostile post-ischemic myocardial microenvironment (Forrester 
et al. 2009, Mohsin et al. 2011) and subsequent optimization of functional engraftment. 
Finally, metabolic flexibility of a quiescent stem cells might be critical for endogenous 
regeneration pointing to oxygen as a major factor for regulation of tissue repair. 
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1.9 CELL-BASED THERAPIES IN HEART FAILURE 
Heart failure, most often subsequent to ischemic heart disease, is a major cause of 
morbidity and mortality worldwide (Roger 2013). After a large myocardial infarction, 
more than a billion cardiomyocytes are lost (Laflamme and Murry 2005), and 
although substantial advances have been made in medical treatment improving the 
prognosis of these patients (Birks et al. 2006), none of the current therapeutic 
approaches directly targets the loss of cardiomyocytes, which is the underlying cause 
of heart failure. 
For decades, the heart was viewed as a terminally differentiated organ lacking the 
regenerative capacity sufficient to replace the loss of myocytes following injury. The 
discovery of endogenous cardiac progenitor cells and reports demonstrating a low 
turnover of existing cardiomyocytes have changed this view to some extent (Hierlihy 
et al. 2002, Beltrami et al. 2003, Bergmann et al. 2009, Porrello et al. 2011, 
Figure 5. Global metabolic changes in cellular fate transitions 
Transition between the naive and primed pluripotent states in human cells is associated with 
changes in the metabolism from predominantly glycolytic to bivalent metabolism utilizing 
both glycolysis and oxidative metabolism. In contrast, upon a differentiation stimulus, 
pluripotent stem cells activate mitochondria biogenesis to generate a robust network of 
mitochondria in support of oxidative metabolism to match lineage-specific energetic demands.  
Reprinted with the permission from the publisher of (Folmes and Terzic 2016) 
http://dx.doi.org/10.1016/j.semcdb.2016.02.010 
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Bergmann et al. 2015). Whether these new cardiomyocytes are derived from 
the proliferation of existing cardiomyocytes or from cardiac progenitor cells is still 
under discussion. 
Multiple candidate cell types have been used in preclinical animal models and in 
humans to repair or regenerate the injured heart either directly or indirectly (through 
paracrine effects). Although no consensus has emerged, the ideal cell type for treatment 
of heart disease should: be safe i.e. not generate tumors nor induce arrhythmias; 
improve heart function; integrate to the host tissue; improve the functional capacity of 
the surrounding cardiomyocytes; stimulate angiogenesis; be delivered by minimally-
invasive clinical methods; be tolerated by the immune system and be ethically 
acceptable (Madonna et al. 2016).   
In the early 1990s the first skeletal myoblasts were isolated, expanded and successfully 
transplanted to an injured heart opening the door for the cardiac cell therapy (Figure 6) 
(Chiu et al. 1995). Since this pioneering work several animal studies have provided 
evidence for the possibility of intra-myocardial myoblast grafting (Taylor et al. 1998, 
Dowell et al. 2003, He et al. 2005, van den Bos et al. 2005). In the first clinical phase I 
trials these cells were implanted concomitantly to coronary artery bypass grafting 
(CABG) (Menasche et al. 2001, Hagege et al. 2003). This study was followed by three 
other adjuncts to CABG studies, reporting similar positive effects on the myocardial 
function (Dib et al. 2005, Gavira et al. 2006). In sharp contrast to the functional benefit 
observed in the early-uncontrolled studies, the first prospective randomized placebo-
controlled phase II trial (MAGIC trial), reported lack of efficacy as well as increased 
early postoperative arrhythmic events (Menasche et al. 2008), thus ending the use of 
myoblasts for heart regeneration. 
Another set of cells that fuelled the field of cardiac regeneration was somatic stem cells, 
among which, the most widely studied are the bone marrow-derived hematopoietic 
stem cells. The study that first explored the potential of hematopoietic stem cells in 
heart regeneration was the study by Orlic and co-workers from 2001(Orlic et al. 2001), 
where they demonstrated that Lin-/ c-Kit+ cells could regenerate 68% of the infarcted 
area in a mouse model. These findings could not be repeated by other groups (Balsam 
et al. 2004, Murry et al. 2004) and according to the results by Nygren and co-workers 
part of the effect exerted by these stem cells might be due to cell-fusion (Nygren et al. 
2004). The relative accessibility of bone marrow, the large numbers of unfractionated 
autologous cells that can be obtained without ex vivo expansion and the extensive 
experience with bone marrow transplantation facilitated clinical application. The BM-
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MNCs used in these clinical trials (Wollert et al. 2004, Schachinger et al. 2006, 
Assmus et al. 2010) were mainly isolated by density centrifugation and the vast 
majority of the cells were committed hematopoietic cells at various stages of 
maturation (Dimmeler and Zeiher 2009). These first generation cell therapies have 
achieved only minor effects (Gyongyosi et al. 2015), possibly attributed to paracrine 
mechanisms without the evidence of replacement of lost cardiomyocytes (Garbern and 
Lee 2013). In a recent meta-analysis of 31 randomized cell therapy trials in heart 
failure, which included 1521 patients, exercise capacity, left ventricular ejection 
fraction (EF), and quality of life were found to be improved in the treated patients 
(Fisher et al. 2015). However, when only double-blind studies were selected, the 
difference was no longer significant (Assmus et al. 2015), (Fisher et al. 2015). The 
effect of BM-MNC therapy on mortality after acute myocardial infarction (AMI) will 
be evaluated in the ongoing phase III BAMI trial (NCT01569178). 
The initial trial with c-Kit+ progenitor cells grown from an intra-operatively 
harvested right appendage biopsy (SCIPIO) had controversial results (Bolli et al. 
2011). 
However, the studies that have compared the effect on cardiac function between 
different cell types, have consistently demonstrated superiority of cardiac-committed 
cells (c-Kit+ or Sca1+ cardiac stem cells, cardiospheres, iPSC-derived cardiomyocytes) 
over cells not committed to a cardiac lineage such as BM-MNCs, MSCs or skeletal 
myoblasts (Matsuura et al. 2009, Rossini et al. 2011, Li et al. 2012). Thus, the next 
generation cell therapies make use of alternative strategies, based upon activation of 
molecular pathways and transcription factors guiding cardiac differentiation (Figure 6). 
Lineage-specified cardiopoietic MSCs, cardiomyocytes derived from embryonic stem 
(ES) cells, or heart fibroblasts directly converted into cardiomyocytes by inducing core 
cardiac transcription factors are being used for cardiac repair in experimental models as 
in clinical trials (Ieda et al. 2010, Song et al. 2012, Bartunek et al. 2013, Chong et al. 
2014, Menasche et al. 2015). By applying similar signals that instruct precardiac 
mesoderm to commit into the cardiomyogenic fate during heart development (Behfar et 
al. 2008), BM-MSCs have been induced to activate a cardiovascular lineage-specifying 
program (Behfar et al. 2010). The first clinically tested example of that approach is 
tested in the C-Cure trial of patients with ischemic cardiomyopathy (Bartunek et al. 
2013). The positive results of the initial C-CURE study (Bartunek et al. 2013)  were 
not, however, reproduced in the European phase III trial Congestive Heart Failure 
Cardiopoietic Regenerative Therapy (CHART-1), which had as a primary efficacy 
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endpoint a composite of mortality, worsening of heart failure, 6-min walk test, left 
ventricular end-systolic volume, and left ventricular EF at 9 months (Bartunek et al. 
2016). 
Another class of the second-generation cells is the PSCs, both ESCs and iPSCs 
(Figure 6). A prerequisite for clinical application of PSCs for heart repair is their 
efficient and strict differentiation into cardiomyocytes and endothelial cells, without 
risk for side effects (Menasche and Vanneaux 2016). The ESCORT trial, a clinical 
trial where ESC-derived Ssea-1+ Isl1+ early mesodermal/cardiac progenitor cells 
embedded in a fibrin scaffold are applied concomitantly with a CABG operation, has 
been initiated in France (Menasche and Vanneaux 2016). The primary end point of 
this pilot phase 1 trial is safety with a particular focus on tumor formation and on 
development of ventricular arrhythmias, since ventricular arrhythmias have been 
reported in the non-human primate study (Chong et al. 2014). iPSC-derived 
cardiomyocytes have not yet been tested in humans, largely because of the increased 
risk of genetic mutation inherent to the reprogramming method as such (Menasche et 
al. 2015). Although PSCs derived cardiac progenitors and direct conversion of 
cardiac fibroblasts into cardiomyocytes hold a great regenerative promise, the 
cardiomyocytes generated by these strategies still possess the immature features of 
embryonic cardiomyocytes (Snir et al. 2003, McDevitt et al. 2005, Abdul Kadir et al. 
2009, Lieu et al. 2009). Future studies are needed to optimize the differentiation 
protocols in order to make these cells more similar to mature ventricular 
cardiomyocytes and thus reduce the risk of arrhythmias (Lambers and Kume 2016).  
Further optimization of cardiac stem cell therapies is needed to increase the pool of 
cardiomyocytes to the level that prevents or reverses the negative remodeling of the 
myocardium in order to prevent heart failure. Consequently, multiple strategies have 
been developed to empower stem cells to survive in the hostile environment through 
pharmacological, genetic or preconditioning interventions (Mohsin et al. 2011). 
Importantly, most studies report a sharp discrepancy between minimal cell 
engraftment of transplanted cells and their putative beneficial effect on preservation 
of left ventricular function (den Haan et al. 2012, Menasche and Vanneaux 2016). 
Yet, the mechanisms of action are only starting to be unraveled. It has been 
demonstrated that cells secrete nano-sized extracellular vesicles (ECV), which can 
transport and transfer microRNAs, proteins, lipids and genetic material, thus 
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activating endogenous cytoprotective pathways (Cheng et al. 2014, Bobis-Wozowicz 
et al. 2015, Zhang et al. 2016).  
In a study by Tseliou et al, cardiosphere-derived ECVs altered the phenotype of 
fibroblasts enabling them to engage in angiogenesis and cardioprotection (Tseliou et 
al. 2015). A precise characterization of cell-released factors accounting for the 
beneficial effects of ECVs remains to be elucidated. Furthermore, there is a need to 
evaluate whether the effect of ECVs on cardiac repair is relevant in a clinical setting 
and in addition, offer major advantages in regard to facilitating the manufacturing 
process as well as circumventing regulatory hurdles that are linked to cell-based 
therapies (Menasche and Vanneaux 2016, Zhang et al. 2016). 
 
Figure 6. The evolution of the stem cell therapy for heart failure. 
 
Initially, the majority of trials used adult stem cells as bone marrow- derived or peripheral blood-
derived MNCs. However, the best outcomes were achieved using therapeutic cells with cardiac 
progenitor characteristics, leading to development of cardiac-committed cell therapies. 
Recent findings are profoundly changing regenerative treatment paradigm by suggesting that 
therapeutic cells act as reservoirs of paracrine factors that may trigger endogenous repair potential. 
Abbreviations: BM: bone marrow, PB: peripheral blood; AT: adipose tissue; iPSCs: induced 
pluripotent stem cells; ESCs: embryonic stem cells; SCs: stem cells. Adapted from (Silvestre and 
Menasche 2015) http://dx.doi.org/10.1016/j.ebiom.2015.11.010 
 
 
A part of this introduction chapter is adopted from our review article with the 
permission of the publisher (Bulatovic et al. 2016). 
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2 AIMS OF THE THESIS 
 
The overall aims of this thesis were to explore the potential of human fetal cardiac 
MSCs to be used for cardiac regeneration and if sublethal apoptotic stimuli and 
metabolic cues could influence cardiomyocyte progenitors plasticity in terms of 
proliferation and differentiation ultimately leading to boost the endogenous 
regenerative potential in injured hearts. 
 
The specific aims of each publication are listed as follows: 
 
Study I: to explore if apoptotic stress in terms of sublethal caspase activation 
influences the proliferation and differentiation of cardiac progenitor cells  
 
Study II: to develop a defined and reproducible protocol for large-scale expansion of 
human fetal cardiac MSCs with cardiac progenitor characteristics to be used for 
generation of endothelial cells, smooth muscle and cardiomyocytes  
 
Study III: to characterize the metabolomic profile of MSCs derived from human fetal 
hearts of the first trimester 
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3 MATERIALS AND METHODS 
 
 
This chapter contains a detailed, comprehensive description of the most relevant 
methods applied in the studies I-III. The additional laboratory techniques are described 
in the respective papers.  
3.1 CELL CULTURE AND DIFFERENTIATION - STUDIES I-III 
 
Mouse Embryonic Stem Cells - Study I  
 
Murine embryonic stem cells (mESC-line CGR8) were kindly provided by Prof. 
Richard Lee, Harvard Medical School. The mESCs were stably transfected with the 
cardiac-specific α-myosin heavy chain (α-MHC) promoter tagged with green 
fluorescent protein (GFP) (Chan et al. 2009). Upon differentiation into 
cardiomyocytes, these cells express GFP, which could be quantified and monitored in 
fixed cells as well as in live cultures. The cells were propagated in Glasgow 
Minimum Essential Medium (GMEM) (Invitrogen) supplemented with 1,000 U/ml 
Leukemia Inhibitory Factor (LIF, ESGRO, Millipore), 1mM Sodium Pyruvate, 1x 
Non-Essential Amino Acid, 15% Knockout Serum Replacement (Invitrogen), 10-
4Mβ-mercaptoethanol, and 1 x Penicillin-Streptomycin. Differentiation was carried 
out as hanging drops in differentiation medium (10% FBS without LIF) in which 
embryoid bodies (EBs) were formed in 2 days (D0–2). For caspase activation 
experiments EBs were cultured in differentiation medium for three weeks, then 
incubated for 5 hr with 100 nM STS followed by a recovery period ranging from 24 
hr to 7 days. 
 
Derivation and Expansion of Human Fetal Cardiac MSCs - Study II and III 
 
The fetal hearts were obtained from legal terminations of pregnancy after the donor’s 
informed consent and ethics approval from the Regional Ethics Board in Stockholm. 
The fetal hearts were pre-digested overnight at 4 C in a 0.5 mg/ml Trypsin solution in 
Hank’s balanced salt solution (HBSS). The MSC fraction was prepared according to a 
modified version of the protocol developed by (Laugwitz et al. 2005). The pre-
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digested heart was treated for 15 min with collagenase type II (Worthington 
Biochemical) 160 U/ml in HBSS, at 37 C under gentle stirring. The supernatant was 
centrifuged at 220 g for 8 min and the pellet resuspended in low-glucose DMEM 
supplemented with 10% fetal bovine serum (FBS) (PAA Laboratories), Mycozap 
(Lonza, Switzerland) and GlutaMAX (Invitrogen). The digestion with collagenase 
was repeated until the tissue was completely dissociated. The pooled cells were 
washed twice and resuspended in the same medium as above. The cells were 
subsequently seeded on plastic and cultured for 96 hr in order to recover the adherent 
fraction and thereafter cryopreserved for later use. The adherent cell fraction obtained 
with this method contains a mixture of different cell types, including the cardiac 
MSCs.  
To activate the transcriptional network known to be involved in embryonic 
cardiogenesis, we focused on the canonical Wnt/β-catenin signaling pathway, which 
has previously been shown to be effective in expansion of SHF progenitors derived 
from embryonic stem cells from mice and humans (Moretti et al. 2006, Qyang et al. 
2007, Bu et al. 2009). 
Based on a strategy previously introduced by Qyang et al., we used a Wnt3a-
containing cell culture medium (Qyang et al. 2007). When cells of the adherent cell 
fraction of human fetal hearts were expanded on plastic, they multiplied rapidly but 
showed a low expression of the cardiac progenitor markers Isl1, Kdr, and Nkx2.5, as 
well as the pluripotency marker Oct4 (Mansson-Broberg et al. 2016). In order to 
improve the culturing conditions, the adherent cells were cultured on dishes pre-
coated with the Engelbreth-Holm Swarm mouse tumor-derived extracellular matrix 
extract, Geltrex (GibcoBRL). This extract, which contains basement membrane 
proteins such as LN-111, has been widely used for culturing stem cells and other cell 
types (Xu et al., 2001; Ludwig et al., 2006). When the adherent cells were cultured on 
Geltrex in combination with Wnt3A-containing medium, the cells divided 
exponentially and were passaged every other day. The cells were seeded at a density 
of 30 000 cells/cm2 on cell culture plastic coated with a thin layer of Geltrex in 
DMEM/F12 supplemented with B27 (GibcoBRL), 2% FBS (PAA), MycoZap 
(Lonza), epidermal growth factor (10 ng/ml) (R&D Systems) and 100 ng/ml 
recombinant human Wnt3A (R&D Systems). In order to validate the cell culture 
protocol, different culturing conditions were tested, where either Geltrex or Wnt3A 
was excluded (gestational weeks 6.5–8, n = 3). After each passage, cells were saved 
for further analyses and at the end of the experiment, at 2 and 3 weeks, the cells were 
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harvested for immunocytochemistry, PCR, and microarray analyses. Exclusion of 
either Wnt3A or Geltrex from the culture protocol negatively affected proliferation of 
the cells in the initial fraction  and preserved survival of the limited numbers of 
remaining cardiomyocytes among the adherent cells. These data suggest that both the 
Wnt3A-containing medium and Geltrex may provide important signals for expansion 
of cells from the adherent cell fraction of fetal human hearts, with transcriptional 
signatures akin to those of cardiac progenitors (Mansson-Broberg et al. 2016). 
 
Laminin-Based Derivation and Expansion of Human Fetal Cardiac MSCs - 
Study II 
 
Cultured pluripotent stem cells and pluripotent cells of the inner cell mass of the 
blastocyst express LN-511 and LN-521 (Rodin et al. 2010). Since these LNs have 
previously been demonstrated to support clonal expansion of cultured embryonic 
stem cells (Rodin et al. 2014) and the LN subunits ɑ5 and γ1 are also abundantly 
expressed in human fetal hearts, this suggests that LN-511 and LN-521 may be 
suitable for derivation and expansion of cardiac MSCs. LN-211, on the other hand, 
might be linked to cardiomyocyte development and/or function, as it has been shown 
to be defective in congenital muscular dystrophic patients with cardiomyopathy 
(Finsterer et al. 2010), and ɑ2 chains were also expressed in the fetal heart. 
To generate chemically defined matrices for derivation and expansion of human fetal 
cardiac MSCs (gestational weeks 6.5–8), the cells were grown in wells coated with 
LN-511, 521, or 211, using the same culture medium as described above. The human 
recombinant laminins were generated as previously described (Kortesmaa et al. 2000, 
Doi et al. 2002, Rodin et al. 2014) or purchased from BioLamina AB (batches 
80,051, 80,050, and 80,042, respectively). 
MSCs cultured on LN-511 and LN-521 displayed a tendency toward increased 
mRNA levels of Isl1 in comparison with cells cultured on Geltrex. For cardiac 
differentiation fetal cardiac MSCs derived and expanded on LN-521 were cultured on 
LN-211 in a medium devoid of Wnt3a. 
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Differentiation of Cardiac MSCs into Cardiomyocytes, Smooth Muscle Cells, 
and Endothelial Cells - Study II  
 
For cardiomyocyte differentiation in vitro we used a modified protocol developed for 
human pluripotent stem cells (Lian et al. 2012), where the cardiac MSCs were 
cultured on Matrigel, LN-211 or plastic. Cardiac MSCs derived from fetal hearts of 
different ages (gestational week 6, 8, and 9, n = 3) were used. Canonical Wnt 
signaling was blocked using a defined serum-free medium to induce cardiomyocyte 
differentiation. After 3 weeks, cells were fixed in 4% phosphate-buffered formalin, 
stained with a mouse monoclonal antibody against human troponin T (TnT) (ab8295, 
clone 1C11, Abcam) and visualized with an Alexa Fluor 488-conjugated rabbit anti-
mouse secondary antibody (A11059, Thermo Fisher Scientific). RNA extraction and 
qRT-PCR for TNNT2 and GAPDH were performed. For imaging calcium signaling 
dynamics, cells were labeled with the Ca2+-sensitive fluorescence indicator Fluo-
4/AM (10 mM; Molecular Probes, Thermo Fischer Scientific) according to the 
manufacturers’ protocol.  
For differentiation toward vascular smooth muscle cells, the cardiac MSCs were 
seeded on gelatin-coated plastic, and cultured for 18 days in a defined medium 
supplemented with PDGF-BB (10 ng/ml) and TGF-1 (2 ng/ml) (PeproTech), 
according to a modified protocol previously described by (Cheung et al. 2014). Cells 
were passaged 1:4 once per week into new gelatin-coated wells. Subsequently, the 
cells were fixed and stained with a mouse antihuman a-smooth muscle actin primary 
antibody (A2547, clone 1A4; Sigma-Aldrich) and visualized by a rabbit anti-mouse 
Alexa Fluor 488-conjugated secondary antibody (Thermo Fischer Scientific). The 
experiment was performed in duplicate using cells from four different hearts of 
gestational age 8 and 9 weeks.  
Endothelial cell differentiation was induced in fetal cardiac MSCs by using a medium 
containing vascular endothelial growth factor (VEGF). The substrates used were 
gelatin or LNs present in the basal membranes of blood vessels (LN-521 and LN-411) 
(Hallmann et al. 2005, Domogatskaya et al. 2012). Fetal cardiac MSCs were seeded 
in culture wells pre-coated overnight with a 1:4 mixture of LN-521/ 411 or gelatin 
(0.1%) and cultured for 21 days in EGM-2 medium (Lonza) with VEGF (50 ng/ml) 
from R&D Systems (Liu et al. 2007). Subsequently, the cells were fixed and stained 
with a monoclonal mouse anti-human CD31 antibody (M0823, clone JC70A). 
Stained cells were visualized using an Alexa Fluor 568-conjugated goat anti-mouse 
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secondary antibody (Thermo Fischer Scientific). The experiment was performed in 
duplicate using cells from five different hearts of gestational age 8 and 9 weeks. 
 
3.2 CONTINUOUS VISUALIZATION OF LIVE CELLS - STUDY I 
Prospective visualization of GFP expression levels was done using CELL-IQ SLF 
continuous live cell imaging and analysis system platform (CM Technologies, 
Tampere, Finland). EBs growing in 24-well dishes were stimulated as indicated and 
then placed into the CELL-IQ imaging system. During the imaging period, conditions 
were maintained at 37°C, 5% CO2. A whole-well fluorescence confocal z-stack 
composed of 6x6 images was taken for each well for every 60 minutes, during a total 
recording time of 72 h. The culture medium was replaced every second day. Single 
cell tracking analysis was performed off-line using CELL-IQ analysis software. 
3.3 MITOCHONDRIAL MORPHOLOGY ASSESSMENT - STUDY III 
In addition to bioenergetic profiling, which reflects the amount of energy being 
produced by mitochondrial versus non-mitochondrial respiration, we assessed another 
dynamic feature that responds to the metabolic needs of the cell, the mitochondrial 
morphology. Presentation of mitochondria as separate organelles is usually associated 
with low activity while elongation and fusion into a network indicates activation and 
increased oxidative phosphorylation (Brand and Nicholls 2011). To visualize 
mitochondria, cells were incubated with MitoTracker Red (500 nM) and Green 
(200nM) (Invitrogen) for 1 hour, following which cells were fixed and visualized with 
confocal microscopy. Electron microscopy (EM) was performed as previously 
described (Folmes et al. 2013).  
3.4 BIOENERGETIC AND METABOLOMIC PROFILING - STUDY III 
Live cell XF24 bioenergetic profiling 
XF24 Extracellular Flux Analyzer (Seahorse Biosciences) allows simultaneous 
assessment of two major cellular energy producing pathways, glycolysis and 
mitochondrial respiration by continuous real-time measurement of pH and oxygen 
concentration in live cells. This automated system measures the extracellular 
acidification rate (ECAR) of the assay medium (lactate, a byproduct of glycolysis, is 
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the major contributor of protons) as a surrogate of glycolytic flux and the oxygen 
consumption rate (OCR), which represents mitochondrial respiration. 
Seahorse XF24 cell culture plates were coated with Geltrex TM (GibcoBRL) over night 
at 4°C, followed by 2 h at 37°C and cells were plated into wells of a XF24 microplate 
and maintained overnight to ensure 80% confluence. For the experiments, 30-50 000 
cells were seeded in each well. Each microplate contained four empty wells that served 
as temperature controls. Prior to assay, plates were equilibrated in the absence of CO2 
for 1 h in unbuffered XF assay medium supplemented with 25 mM glucose, 2 mM 
glutamax, 1 mM sodium pyruvate, 1x nonessential amino acids and 1% FBS.  
The Seahorse XF24 uses modulators of respiration that target components of the 
electron transport chain (ETC) in the mitochondria to measure key parameters of 
metabolic function. Oligomycin inhibits ATP synthase (complex V) and the decrease in 
OCR following injection of oligomycin correlates to the mitochondrial respiration 
associated with cellular ATP production. Carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP) is an uncoupling agent that collapses the proton gradient and 
disrupts the mitochondrial membrane potential. As a result, electron flow through the 
ETC is uninhibited and oxygen is maximally consumed by complex IV. The FCCP-
stimulated OCR can then be used to calculate respiratory capacity, defined as the 
difference between maximal respiration and basal respiration. Respiratory capacity is a 
measure of the ability of the cell to respond to increased energy demand. The third 
injection is a mix of rotenone, a complex I inhibitor, and antimycin A, a complex III 
inhibitor. This combination shuts down mitochondrial respiration and enables the 
calculation of nonmitochondrial respiration driven by processes outside the 
mitochondria. In our experiments mitochondrial processes were interrogated by serial 
addition of oligomycin (0.5 g/ml), FCCP (1 M) rotenone (Rot, 0.5 M) and 
antimycin (AntA, 1mM). The following OxPhos indexes were calculated: basal 
respiration (OCRpre-Olig - OCRpost-AntA), ATP-linked respiration (OCRpre-Olig - 
OCRpost-Olig), maximal respiration (OCRpost-FCCP - OCRpost-AntA) and 
respiratory capacity (OCRpost-FCCP - OCRpre-Olig). Each plotted value is the mean 
of 6 to 10 replicate wells, and is normalized to total protein quantified using a Bradford 
protein assay (Bio-rad). All data are presented as mean±SD from three separate 
experiments performed. Statistical differences were calculated using the Student's t test 
and considered significant at *p<0.05. 
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Cell preparation for nuclear magnetic resonance spectroscopy (NMR) 
 
After harvesting, cell extraction was performed on 1-10×10
6cells per sample. 500 μl of 
a 2:1 (v/v) ratio of ice-cold methanol/chloroform was added to the frozen cell pellet, 
and the pellet–solvent mixture was sonicated for 4 min. Then, 500 μl of ice-
cold1:1(v/v) chloroform/water was added and mixed to form an emulsion. After 
approximately 15 min, the samples were centrifuged at 13 000 rpm for 20 min. The 
upper phase (methanol and water) and lower phase (organic) were removed and placed 
in separate Eppendorf tubes taking care not to disturb the pelleted debris. The solvent 
was dried and the tubes were placed in a freezer until analyzed. For the NMR 
experiment, the lyophilized extracts were dissolved in 0.1 M phosphate buffer (pH 7.0) 
and 10% v/v D2O contained DSS (4, 4-dimethyl-4-silapentane-1-sulfonic acid), which 
is a chemical compound used in proton- and carbon-related NMR spectroscopy, as 
internal standard. Three samples per group were prepared in 5-mm NMR tubes 
(Optima Inc., Elk Grove Village, IL, USA). NMR spectra were recorded on a Bruker 
500 MHz NMR spectrometer using noesypr1d pulse sequence with an 11160.7 Hz 
spectral width, 32k points, acquisition time of 1.4680 s, relaxation delay of 14 s and 64 
scans. Spectra were processed with exponential line broadening to 0.3 Hz, zero filled to 
64k points, and manually phase corrected using Topspin 3.1 prior to submission to 
Chenomx software for NMR data analysis. 
 
Metabolomic footprinting 
 
Extracellular metabolites (“metabolomic footprint”) were quantified using proton 
nuclear magnetic resonance spectroscopy (1H NMR)(Folmes et al. 2011). Media 
samples were serially collected at 24 h. Media (540L) was then added to 60 L of 
D2O (Sigma) containing 5 mM sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 (TSP) 
(Sigma) for chemical shift reference and 81.84 mM formate (Sigma) for peak 
quantification reference. p-Toluene sulfonic acid (Sigma) was utilized as a reference 
standard to calibrate the formate concentration for quantitative analysis. Samples were 
filtered through Costar Spin-X filters and added to 5 mm NMR tubes 
(WilmadLabglass) for 1H NMR analysis on a BrukerUltrashield 700 MHz 
spectrometer using a zgpr water pre-saturation pulse with an 11160.7 Hz spectral width, 
32,000 points, acquisition time of 1.4680 s, relaxation delay of 14 s and 64 scans. 
Spectra were processed with exponential line broadening to 0.3 Hz and zero filling to 
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65,000 points. Following Fourier transformation, spectra were autophased with phase 
correction, baseline corrected using a Bernstein polynomial fit and referenced to the 
TSP peak (0.00 ppm) using MestReNova 5.3.2 (MestRelab Research). Metabolite 
identities were assigned by comparison to reference values for chemical shift and 
multiplicity, and confirmed by comparison to spectra of pure compounds in the Human 
Metabolome database (Govindaraju et al. 2000, Wishart et al. 2009). Net fluxes of 
metabolites were calculated by subtracting normalized concentrations of metabolites in 
basal media from concentrations of metabolites in 24-h conditioned media. Rates were 
normalized to total cellular protein content determined by a Bradford protein assay 
(Bio-rad).  
 
Spectral analysis and statistical analysis 
 
The NMR data sets were referenced to DSS signal and baseline-corrected in the 
ChenomxNMR Suite 5.1 (Chenomx Inc., Edmonton, AB, Canada). Metabolite 
concentrations were measured using the 500 MHz library from ChenomxNMR Suite 
version 5.1, which uses the concentration of a known reference signal (DSS) to 
determine the concentration of individual compounds. The library is based on a 
database of individual metabolite spectra acquired using the NOESYPRESAT 
sequence. For multivariate statistical analysis spectra were binned (equidistant 0.04 
ppm binning) with total peak area normalization and solvent region removal (4.68-5.00 
ppm). Orthogonal projection to latent structures discriminant analysis (OPLS-DA) was 
carried out to discriminate between groups using SIMCA-P (version 11, Umetric, 
Umea, Sweden). The OPLS model maximizes the covariance between the measured 
data of X variable (peak intensities in NMR spectra) and the response of Y variable 
(classification components) within the groups. All data are presented as mean±SD from  
three separate experiments performed. Statistical differences were calculated using the 
Student's t test and considered significant at *p<0.05. 
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4 SUMMARY OF RESULTS 
 
4.1 STUDY I 
In response to apoptotic stress the adult heart reactivates gene expression programs 
normally found in the prenatal heart, which, in turn, is thought to allow protective 
changes of cell survival mechanisms, metabolism and contractility (Rajabi et al. 
2007). Additionally, the dedifferentiation of adult cardiomyocytes was proposed as a 
mechanism of heart regeneration in zebrafish and neonatal mice (Jopling et al. 2010, 
Porrello et al. 2011). Based on these findings, in the Study I we initially hypothesized 
that proliferating progenitors could be derived from mature cardiomyocytes by first 
inducing and subsequently intercepting a programmed cell death response. However, 
finding the optimal model to explore this hypothesis in vitro has proved to be a 
challenge since adult cardiomyocytes were shown to spontaneously dedifferentiate in 
culture (Zhang et al. 2010). Therefore, we chose to optimize the sublethal apoptosis 
induction protocol on mouse ESCs that have been differentiated for three weeks, since, 
after that time point, most of the beating cardiomyocytes had stopped proliferating.  
Treatment with nano-molar concentrations of the broad-spectrum apoptotic agent, 
Staurosporine (STS), induced activation of caspase-3 and -9, but failed to promote cell 
death. Sublethal caspase activation led to increased yield of cardiomyocytes, detected 
as increase of GFP expression, which was under control of the α-myosin heavy chain 
(α-MHC) promoter and up-regulation of mRNAs levels of specific cardiomyocyte 
markers (Figure 7). The broad-spectrum caspase inhibitor Q-VD-OPH abolished these 
effects. Interestingly, beating clusters of cells with low GFP expression were also 
observed following STS exposure, but not in the untreated control cells (Figure 7). 
Further investigation using single cell tracking is required to understand with certainty 
whether these early cardiomyocytes with low α-MHC expression were generated from 
cardiac progenitor cells or dedifferentiated cardiomyocytes.  
Additionally, in our study, a broad caspase inhibition prevented up-regulation of 
cardiac-specific markers during EB-differentiation, similarly to what has been 
described for skeletal muscle differentiation (Murray et al. 2008) (Figure 8). 
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Figure 7. Cardiac differentiation is enhanced in response to sublethal proapoptotic 
stimuli 
Mouse ESCs, stably transfected with a GFP reporter under the control of the α-MHC 
promoter were cultured as embryonic bodies in differentiation medium for three weeks 
followed by 5 h incubation with 100 nM STS. After a 96 h recovery, we observed an increase 
in the proportion of GFP+ cells in STS treated EBs. Beating clusters of cells with low GFP 
expression were also observed following STS exposure, but not in the untreated control cells 
(A).  Pre-incubation of EBs with a broad- spectrum caspase inhibitor, Q-VD-OPH prevented 
the effects induced by STS (A and B). Subsequently, we continuously monitored GFP levels 
for 3 days after STS treatment using long-term live cell imaging. In control cells, GFP levels 
remained unaltered, while STS treatment significantly increased the GFP levels in single 
cells, which is under control of the α-MHC promoter, suggesting increased differentiation of 
early cardiomyocytes (C and D). TnT (E), α-MHC (F), and Nkx2.5 (G) mRNA expression 
levels were significantly up-regulated in STS-treated cells after 3 and 7 days of culture, 
whereas the expression of Oct4 (H), a hallmark of pluripotency, was downregulated.  
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Figure 8. Caspase inhibition suppresses cardiac differentiation 
 
When a broad- spectrum caspase inhibitor Q-VD-OPH was added to the differentiating EB 
cultures we found that the levels of α-MHC (A) and Nkx2.5 (B) significantly decreased by 
acute Q-VD-OPH treatment (5h), while chronic treatment (24 h and 48 h) only affected α-
MHC expression. In contrast, Isl1 expression (C) was strongly up-regulated by acute Q-VD 
treatment.  
 
 
 
A mechanism of action by which active caspase 3 induces cardiac differentiation 
might be through cleavage and activation of mitogen-activated protein kinase 
(MAPK) signaling cascades (MST1/MKK6/p38) (Fernando et al. 2002). Downstream 
components of these cascades up-regulate Mef2a and c factors known to be important 
for cardiomyocyte differentiation (McKinsey et al. 2000). In the work by Abdul-
Ghani et al. (Abdul-Ghani et al. 2011), the authors demonstrated that caspases have a 
role in cardiac differentiation mediated through their proteolytic cleavage of β-
catenin, leading to a loss of canonical Wnt signaling activity (Steinhusen et al. 2000).  
Whereas the response to injury is intensively studied in the adult heart, much less is 
known about response to apoptotic stimuli in embryonic cardiomyocytes. Recently, a 
systematic and comprehensive characterization of stress response, using a model of 
tissue mosaicism for mitochondrial dysfunction in prenatal mouse hearts, showed an 
impressive ability of embryonic cardiomyocytes to adapt to stress (Magarin et al. 
2016), which is in line with our observations. However, additional studies are 
necessary to determinate the exact cell populations responsive to caspase activation as 
well as to further dissect the mechanism of action of caspases in the embryonic heart. 
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Taken together, our findings provide insights into the fate decisions that regulate cell 
death or differentiation, by which stem cells with cardiac differentiation potential may 
become activated following injury.  
4.2 STUDY II 
 
The optimal cells for heart regeneration should be able to proliferate in damaged 
myocardium while differentiating into endothelial cells, smooth muscle, and 
cardiomyocytes. In Study II we describe that by culturing fetal cardiac MSCs on 
biologically relevant laminins (LN) in a medium containing molecules stimulating the 
Wnt/-catenin pathway we can generate cells with cardiac progenitor characteristics. 
Furthermore, this culture system promotes large-scale production of cardiac MSCs, 
while retaining their cardiovascular progenitor phenotype, with low gene-expression 
variability during the course of culture. The gene-expression profile of the human 
fetal cardiac MSCs showed core group of transcription factors known to be important 
in the regulation of cardiogenesis, including the expression of mesodermal markers: 
Tbx6, Tbx1/Brachyury, Tbx18, and Mesp1; key transcription factors involved in the 
SHF development in mice (Black 2007): Isl1, Gata4, Nkx2.5, Foxh1, Fgf8; the FHF 
(Tbx5, Nkx2.5), as well as other markers related to cardiovascular progenitors like 
Pdgfrα  and the stemness markers Kdr, Ssea-1, and c-Kit.  However, the cultured 
cardiac MSCs also expressed mature cardiomyocyte markers such as myosin heavy 
chain (Myh) 6 and 7, the endothelial marker Vcam1, as well as the smooth muscle 
markers Myh11 and myocardin (Myocd). These cells can be directed towards 
cardiomyocytes using LN-211 and can also be differentiated into endothelial cells and 
smooth muscle cells (Figure 9).  
Interestingly, the use of specific LN molecules supported lineage conversion of the 
cultured cardiac MSCs into cardiomyocytes and endothelial cells. Using LN-211 
alone, the main component of the basement membrane surrounding adult cardiac and 
skeletal muscle fibers in situ (Domogatskaya et al. 2012), stimulated cardiac 
commitment of fetal cardiac MSCs at the gene-expression level, with a 150 times 
increase of TnT expression and a concomitant up-regulation of Nkx2.5. In addition, 
culture on LN-521/411, which is present in the basal membranes of vessels (Hallmann 
et al. 2005, Simon-Assmann et al. 2011, Domogatskaya et al. 2012), supported 
differentiation toward endothelial cells expressing CD31.  
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Figure 9. Derivation of human fetal cardiac MSCs with cardiac progenitor 
characteristics 
 
In order to develop a culture protocol for successful propagation of cardiac MSCs, we started 
from the adherent cell fraction from whole human fetal hearts (gestational weeks 6–10). At 2 
weeks, the adherent cells had expanded more than 1,000-fold and demonstrated activation of 
transcription factors involved in defining cardiac progenitors and multi-potent stem cells. 
After 3 weeks in culture the majority of cardiac MSCs stained positive for Isl1 (>90%) and 
Nkx2.5 (>80%). A portion of the cultured cardiac MSCs derived from the 9-week heart 
differentiated within three weeks into spontaneously beating, TnT+, striated cardiomyocytes. 
Endothelial cell differentiation was induced in cardiac MSCs by using a combination of 
medium containing vascular endothelial growth factor (VEGF) and LNs present in the basal 
membranes of blood vessels (LN- 521 and LN-411) as substrata. After 3 weeks in culture, a 
small proportion of the cardiac MSCs expressed the endothelial marker CD31. The fetal 
cardiac MSCs expressed α-SMA prior to differentiation. Interestingly, after smooth muscle 
cell differentiation, the α -SMA polarized into podosome-like structures, which can be found 
in vascular smooth muscle cells upon stimulation with exogenous PDGF-BB and TGF-ß.  
 
These characteristics of fetal cardiac MSCs indicate their plasticity as well as the 
potential use of combinations of these cells, specific laminins and signaling molecules 
for generation of cardiac progenitor cells for cardiac repair. 
The origin of the different subpopulations of cardiac MSCs has not been examined in 
this study. In the present study, the majority of the cultured cardiac MSCs stained 
positive for Pdgfrα. Whether these cells possibly originate from interstitial cells of the 
atria and ventricles remains to be elucidated, but they displayed a similar capacity to 
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differentiate into endothelial cells and also cells with polarized α -SMA expression 
akin to that of mature smooth muscle cells. In contrast to the Pdgfrα+ cells derived 
from second trimester hearts (Chong et al. 2013), the fetal cardiac MSCs derived 
from a 9-week human heart could be differentiated into spontaneously beating, 
striated TnT+ cardiomyocytes. However, the cells derived from 6- to 8-week human 
fetal hearts did not differentiate into TnT+ cardiomyocytes, despite similar expression 
of Isl1, Nkx2-5, Pdgfrα, Ssea-1, Kdr, and c-Kit before initiation of differentiation. 
This restricted differentiation capacity might be related to the age of the fetal heart 
from which the cardiac MSCs were derived. However, age-related differences in 
expression of markers known to characterize cardiovascular progenitors were not 
observed in this study. Some of the cultured cardiac MSCs also stained positive for 
the mesodermal progenitor marker Tbx18 (Christoffels et al. 2006, Mommersteeg et 
al. 2010) and future studies need to be performed in order to address whether some of 
the Pdgfrα + and Tbx18+ cells potentially share a developmental origin.  
4.3 STUDY III 
 
In Study III, we performed bioenergetic profiling of cardiac MSCs derived from human 
fetal hearts from gestational weeks 4.5 to 10.5 and cultured under standard conditions 
in normoxia. The basal and ATP-linked (mitochondrial) respiration, as well as the 
maximal respiration levels increased significantly over time during the first trimester 
indicating that active OxPhos is likely required to meet high ATP demands needed for 
extensive biosynthesis during fetal heart development.  
Mitochondria are known to change morphology in accordance with the metabolic needs 
of the cell. We observed predominantly perinuclear accumulation of mitochondria in 
human fetal cardiac MSCs with a distinctive crypta formation and elongated 
morphology. Mitochondria in the cardiac MSCs derived from the 5
th 
gestational week 
are presented as separate organelles, while instead, mitochondria of MSCs derived from 
hearts from the end of the first trimester formed a network. Mitochondrial network 
formation indicates mitochondrial activation, which is in accordance with our 
bioenergetic profiling data that shows increased OxPhos in later gestational weeks. 
In Study II, the cells derived from a 9-week heart showed most pronounced cardiogenic 
capacity and were able to give rise to spontaneously beating cardiomyocytes. 
Accordingly, in Study III, human fetal cardiac MSCs derived from the same 9-week 
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heart that previously demonstrated cardiogenic capacity, showed an increase in 
mitochondrial OxPhos after three weeks of stimulation with Wnt3a. This change might 
support the propagation of cells with cardiac progenitor characteristics from the MSCs 
of the 9-week heart, since more effective ATP production is crucial for contractile cells. 
The developmental dynamics of the glycolytic to OxPhos transfer network is distinctive 
for the remodeling of cellular energetic infrastructure underlying stem cell 
cardiogenesis (Chung et al. 2007, Ellen Kreipke et al. 2016). Thus, the human fetal 
cardiac MSCs´ ability to respond to prolong Wnt3a stimulation with increased OxPhos 
activation seems to be predictive for their cardiac lineage commitment.  
This observation warrants further investigation as it may provide clues for developing 
new approaches that will allow manipulation of the fate and lineage specification of the 
MSCs, in a similar way to the recent mass production of functional cardiomyocytes 
from human ESCs achieved by changing the primary carbon source in growth media 
from glucose to lactate (Tohyama et al. 2013).   
In conclusion, our findings provide important insights on the distinct bioenergetics of 
fetal cardiac MSCs during heart development. Optimal metabolic conditions do not 
only need to be permissive for the expansion and directed differentiation of cells, but 
could also serve as instructive regulatory signals leading to development of new drugs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46 
5 CONCLUSIONS 
 
 
 
I. Sublethal caspase activation increases the yield of early cardiomyocytes 
derived from mouse ESCs, whereas caspase inhibition decreases 
cardiomyogenesis  
 
II. Multi-potent human cells with cardiac progenitor characteristics can be 
propagated from MSCs of fetal hearts by using a combination of canonical 
Wnt/β-catenin stimulation and specific laminin isoforms as cell culture 
substrata 
 
III. Metabolomic profiling of human fetal cardiac MSCs shows increase in 
oxidative phosphorylation during first trimester development as well as during 
their expansion towards multi-potent cells with cardiac progenitor 
characteristics. 
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6 GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
 
Regenerative cardiology that initially aimed to directly replace lost cardiomyocytes 
with exogenous stem cells has undergone a profound paradigm shift, leading us to 
consider that therapeutic activity reflects primarily an indirect, paracrine effect of 
delivered cells to trigger an endogenous regenerative cascade.  However, the incidence 
of reparative stem cells with a clinically measurable cardio-regenerative capacity is 
rather rare in patient cohorts (Cogle et al. 2014). Patient's age, sex, morbidities, and 
concomitant therapies may impact regenerative potential. It has been suggested that 
non-regenerative cells remain confined to a state of perpetual stemness (Marban and 
Malliaras 2012), whereas regenerative cells are environment responsive, plastic, with 
an inclination towards cardiovascular lineage specification (Behfar et al. 2010, Terzic 
and Behfar 2016).  
Bone marrow-derived MSCs represent a rare population of multi-potent stem cells, 
capable to differentiate into osteoblasts, adipocytes, chondrocytes, muscle cells and 
stromal fibroblasts (Friedenstein et al. 1968, Caplan 1991, Prockop 1997, Pittenger et 
al. 1999). MSCs feature several clinically relevant advantages such as ease of isolation, 
high expansion potential with stable gene expression as well as immunomodulatory 
capacities (Le Blanc et al. 2008). 
However, there are also major limitations related to BM-MSCs, for instance their 
tendency to lose clonogenicity and differentiation capacity when expanded in vitro, 
which might affect the outcome upon use in clinical trials. Age of the donor, plating 
density, serum composition and passage time have all been implicated in MSCs 
senescence. In order to by-pass these issues, it is important to continue developing 
expansion protocols of MSCs to preserve their multi-potency and immunomodulatory 
ability. 
In the POSEIDON randomized trial where autologous and allogeneic MSCs were 
compared in patients with ischemic cardiomyopathy, these cells demonstrated limited 
effect on the functional capacity as well as the remodeling of the left ventricle (Hare et 
al. 2012). This trial proved the safety of allogeneic MSCs for clinical use, as previously 
demonstrated in studies in graft versus host disease (Le Blanc et al. 2008).  
One strategy to make implanted MSCs more homogenous is to prime them into 
cardiopoietic MSCs. Using the same embryonic signals that instruct precardiac 
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mesoderm into the cardiomyogenic fate (Behfar et al. 2008), it is possible to impose a 
lineage-specifying program on stem cells (Behfar et al. 2010). In a clinical phase I/II 
trial (C-Cure trial) in patients with ischemic cardiomyopathy, the cell-treated group 
demonstrated improved EF as well as functional capacity in comparison to the control 
group (Bartunek et al. 2013). However, these effects were not reproduced in the 
European phase III multi-center trial CHART-1. (http://www.celyad.com/news/celyad-
announces-results-for-the-chart-1-phase-iii-clinical-trial-evaluating-c-cure-cell-
therapy). 
Based on previous studies, the optimal cells for heart regeneration should be able to 
survive in the injured myocardium while exerting beneficial effects on the surrounding 
cells by stimulating angiogenesis and inhibiting apoptosis of cardiomyocytes. In paper 
II, we have developed a protocol to derive and expand human fetal cardiac MSCs with 
characteristics of multi-potent cardiac progenitor cells. We used biologically defined 
culture conditions by employing specific laminins in combination with canonical Wnt/ 
β-catenin stimulation.  
Based on our preliminary results, when using the same protocol on the adult BM-
MSCs, these culture conditions enhanced proliferation, clonogenicity, multi-potency, as 
well as immunomodulatory and cardiogenic lineage specification, all of which may 
significantly improve the therapeutic potential. If our concept is reproducible in mature 
BM-MSCs, it would enable us to expand allogeneic BM-MSCs into large number of 
cells with cardiac progenitor characteristics to be used at the time of myocardial 
infarction, preventing the remodeling process and the development of heart failure.  
Beyond traditional focus on induced expression of cardiac specific transcription factors, 
to direct the stem and progenitor cells towards cardiovascular fate, the recent studies of 
stem cells metabolism are revealing clues about potential metabolic signatures 
distinctive for cells with higher regenerative capacity and cardiogenic potential.  
In study III we suggest that a deeper understanding of metabolism in quiescent stem 
cells is necessary to define optimal in vitro conditions for expansion and differentiation 
of MSCs, improving survival and engraftment in vivo. These strategies might be 
important to define the criteria to choose the MSCs with the best regenerative potential 
to be used in clinical trials. In a clinical setting, the optimal metabolic state of the 
implanted cells might differ if these cells are used for treatment in the acute or chronic 
phase of heart failure.  
In the MSCs derived from fetal hearts during the first trimester of gestation, we 
observed increase in aerobic mitochondrial metabolism. Furthermore, stimulation of the 
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canonical Wnt/ β-catenin signaling pathway in hypoxia appeared to enhance long-term 
MSC expansion and resulted in a cell population with higher cardiogenic differentiation 
potential. 
The embryonic heart has an impressive regenerative capacity (Sturzu et al. 2015, 
Magarin et al. 2016) and Porrello and colleagues have demonstrated that the mouse 
heart can still fully regenerate if amputation of the ventricular apex occurs on the first 
neonatal day (Porrello et al. 2011). However, this initial robust regenerative potential is 
rapidly lost already within the first postnatal week (Porrello et al. 2011). Interestingly, 
immediately after birth the cardiomyocytes produce more than half of their ATP 
through glycolysis, while at seven days after birth, glycolysis decreases accounting for 
less than 10% of the ATP production (Lopaschuk and Jaswal 2010). Recent report 
from Puente et al. indicated that the increase in environmental oxygen, and the 
subsequent upregulation of oxidative metabolism is the upstream signal that triggers 
cell cycle exit of cardiomyocytes shortly after birth (Puente et al. 2014). Additionally, 
by fate mapping of hypoxic cells, Kimura et al. identified a rare population of hypoxic 
cardiomyocytes in the adult mice that display characteristics of proliferative neonatal 
cardiomyocytes (Kimura et al. 2015). These results suggest that hypoxia signaling is an 
important hallmark of cycling cardiomyocytes. Indeed, distinct metabolic signature of 
fetal cardiac cells may contribute to remarkable regenerative ability of the fetal and 
neonatal heart. 
Based on these findings it is tempting to speculate that, the reactivation of fetal 
survival mechanisms in the adult heart represents an attractive therapeutic goal. 
Mature cardiomyocytes were shown to have a capacity to dedifferentiate in response to 
specific stimuli (Kubin et al. 2011) and differentiated, multinucleated skeletal muscle 
cells can be dedifferentiated into proliferating progeny by first inducing and 
subsequently intercepting a programmed cell death response (Wang et al. 2015). 
Recently, the role of caspases in promoting differentiation of embryonic stem cells 
(Fujita et al. 2008) made these proteases attractive candidates in regulating 
differentiation rather than just executers of programmed cell death. In paper I, we 
described that a sublethal apoptotic stimulus triggers a caspase-dependent signaling 
mechanism and increases the yield of early cardiomyocytes derived from mouse ESCs 
(Bulatovic et al. 2015). In a clinically relevant setting, our results suggest that caspase-
controlled pathways may have a role in bridging an acute cell injury to the fate decision 
of exogenous and endogenous cell sources. It was previously reported that the exposure 
of cells to sublethal hypoxia increased the their tolerance to the harsh environment after 
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transplantation (Yu et al. 2013). These preconditioned cells also showed increased 
differentiation, enhanced paracrine effects leading to increased trophic support, and 
improved homing to the site of the lesion (Yu et al. 2013).  If the induction of sublethal 
apoptotic stimuli can stimulate generation and proliferation of new cardiomyocytes in 
human embryonic stem cells and in vivo after a myocardial infarction and if this 
approach can be combined with cellular therapy or delivery of drug-loaded ECVs needs 
to be further explored.  
In conclusion, by creating reliable maps of cardiovascular progenitors and their 
metabolic state, it may become possible to generate highly expandable cells with 
cardiac progenitor properties from adult MSCs, while preserving their 
immunomodulatory characteristics and create an off-the-shelf system for use in an 
acute and chronic setting.  
Finally, this thesis explores a role of apoptotic stimuli and metabolic flexibility in 
cardiac progenitor fate determination. The future approach based on deeper 
understanding and targeted manipulation of these signals may enhance the heart's 
intrinsic regenerative capacity through activation of endogenous progenitor cells or 
stimulation of cell cycle reentry in adult cardiomyocytes. 
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